Vancomycin is extensively evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4 studies. Sponsored by academic and medical research institutions such as Vanderbilt University Medical Center, NYU Langone Health, and Erasmus Medical Center, these studies range from pending protocols to active recruitment and completion. The research investigates diverse conditions and therapeutic applications, including community-acquired pneumonia, surgical site infections, catheter-related infections, bacteremia, vancomycin-resistant enterococci colonization, and surgical intrawound administration.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06794944 | NOT_YET_RECRUITING | Inflammatory Bowel Disease (IBD); Clostridioides Difficile Infection |
Brigham and Women's Hospital |
2026-09 | PHASE4 |
| NCT06794944 | NOT_YET_RECRUITING | Inflammatory Bowel Disease (IBD); Clostridioides Difficile Infection |
Brigham and Women's Hospital |
2026-09 | PHASE4 |
| NCT07328971 | RECRUITING | Clostridia Difficile Colitis |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2026-04-24 | PHASE3 |
| NCT07328971 | RECRUITING | Clostridia Difficile Colitis |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2026-04-24 | PHASE3 |
| NCT07283068 | NOT_YET_RECRUITING | Revision Total Knee Arthroplasty |
The Methodist Hospital Research Institute |
2026-06-15 | |
| NCT07283068 | NOT_YET_RECRUITING | Revision Total Knee Arthroplasty |
The Methodist Hospital Research Institute |
2026-06-15 | |
| NCT07435051 | NOT_YET_RECRUITING | Osteomyelitis (Refractory) |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-05-01 | PHASE3 |
| NCT07435051 | NOT_YET_RECRUITING | Osteomyelitis (Refractory) |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-05-01 | PHASE3 |
| NCT04793152 | RECRUITING | MRSA |
Anthony Bai |
2023-03-20 | |
| NCT04793152 | RECRUITING | MRSA |
Anthony Bai |
2023-03-20 | |
| NCT06954129 | RECRUITING | Acute Kidney Injury |
University of Pennsylvania |
2026-01-28 | PHASE4 |
| NCT06954129 | RECRUITING | Acute Kidney Injury |
University of Pennsylvania |
2026-01-28 | PHASE4 |
| NCT07478848 | RECRUITING | Large B Cell Lymphoma; Non Hodgkin Lymphoma (NHL); Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed |
Abramson Cancer Center at Penn Medicine |
2026-05-29 | PHASE1 |
| NCT07478848 | RECRUITING | Large B Cell Lymphoma; Non Hodgkin Lymphoma (NHL); Diffuse Large B Cell Lymphoma (DLBCL); Diffuse Large B Cell Lymphoma Refractory; Diffuse Large B Cell Lymphoma Relapsed |
Abramson Cancer Center at Penn Medicine |
2026-05-29 | PHASE1 |
| NCT04993027 | NOT_YET_RECRUITING | Infection of Total Hip Joint Prosthesis; Infection of Total Knee Joint Prosthesis |
Alberta Hip and Knee Clinic |
2025-12-30 | PHASE2 |
| NCT04993027 | NOT_YET_RECRUITING | Infection of Total Hip Joint Prosthesis; Infection of Total Knee Joint Prosthesis |
Alberta Hip and Knee Clinic |
2025-12-30 | PHASE2 |
| NCT05571722 | RECRUITING | Antibiotic Prophylaxis; General Surgery |
Assistance Publique Hopitaux De Marseille |
2024-11-12 | PHASE4 |
| NCT05571722 | RECRUITING | Antibiotic Prophylaxis; General Surgery |
Assistance Publique Hopitaux De Marseille |
2024-11-12 | PHASE4 |
| NCT05137119 | RECRUITING | Staphylococcus Aureus Bacteremia |
University of Melbourne |
2022-02-16 | PHASE4 |
| NCT05137119 | RECRUITING | Staphylococcus Aureus Bacteremia |
University of Melbourne |
2022-02-16 | PHASE4 |
| NCT04825522 | RECRUITING | Spine Disease |
Windsor-Essex Compassionate Care Community |
2022-03-27 | PHASE4 |
| NCT04825522 | RECRUITING | Spine Disease |
Windsor-Essex Compassionate Care Community |
2022-03-27 | PHASE4 |
| NCT05169229 | RECRUITING | Arthroplasty, Replacement, Hip; Osteoarthritis, Hip; Antibiotic Resistant Infection; Prosthetic Joint Infection |
University Hospital, Linkoeping |
2022-04-01 | PHASE2 |
| NCT05169229 | RECRUITING | Arthroplasty, Replacement, Hip; Osteoarthritis, Hip; Antibiotic Resistant Infection; Prosthetic Joint Infection |
University Hospital, Linkoeping |
2022-04-01 | PHASE2 |
| NCT06126614 | RECRUITING | Periprosthetic Joint Infection |
Hamilton Health Sciences Corporation |
2024-05-07 | PHASE3 |
| NCT06126614 | RECRUITING | Periprosthetic Joint Infection |
Hamilton Health Sciences Corporation |
2024-05-07 | PHASE3 |
| NCT06979609 | RECRUITING | Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; Clostridoides Difficile Associated Disease |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2025-11-01 | PHASE2; PHASE3 |
| NCT06979609 | RECRUITING | Clostridioides Difficile Infection; Clostridioides Difficile Infection Recurrence; Clostridoides Difficile Associated Disease |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2025-11-01 | PHASE2; PHASE3 |
| NCT04678154 | RECRUITING | Post Operative Surgical Site Infection |
Major Extremity Trauma Research Consortium |
2021-05-07 | PHASE3 |
| NCT04678154 | RECRUITING | Post Operative Surgical Site Infection |
Major Extremity Trauma Research Consortium |
2021-05-07 | PHASE3 |
| NCT06504992 | NOT_YET_RECRUITING | Open Fracture; Trauma; Infection, Surgical Site; Fractures, Open; Wound Infection; Fractures, Bone; Post-Operative Wound Infection |
University of Manitoba |
2024-11-01 | PHASE4 |
| NCT06504992 | NOT_YET_RECRUITING | Open Fracture; Trauma; Infection, Surgical Site; Fractures, Open; Wound Infection; Fractures, Bone; Post-Operative Wound Infection |
University of Manitoba |
2024-11-01 | PHASE4 |
| NCT07756255 | NOT_YET_RECRUITING | ADHD; ADHD - Attention Deficit Disorder With Hyperactivity; ADHD - Combined Type |
University of Calgary |
2026-08-31 | PHASE2 |
| NCT07756255 | NOT_YET_RECRUITING | ADHD; ADHD - Attention Deficit Disorder With Hyperactivity; ADHD - Combined Type |
University of Calgary |
2026-08-31 | PHASE2 |
| NCT07031999 | NOT_YET_RECRUITING | Implant Failure; Infection |
Hospital Universitario Evangelico de Curitiba |
2026-06-01 | PHASE1; PHASE2 |
| NCT07031999 | NOT_YET_RECRUITING | Implant Failure; Infection |
Hospital Universitario Evangelico de Curitiba |
2026-06-01 | PHASE1; PHASE2 |
| NCT07556107 | RECRUITING | Infection; Acute Kidney Injury; Sepsis |
Bassett Healthcare |
2026-08-17 | PHASE4 |
| NCT07556107 | RECRUITING | Infection; Acute Kidney Injury; Sepsis |
Bassett Healthcare |
2026-08-17 | PHASE4 |
| NCT06567808 | NOT_YET_RECRUITING | Infection, Surgical Site |
Hamilton Health Sciences Corporation |
2026-03-01 | PHASE4 |
| NCT06567808 | NOT_YET_RECRUITING | Infection, Surgical Site |
Hamilton Health Sciences Corporation |
2026-03-01 | PHASE4 |
| NCT06439953 | RECRUITING | Post-Op Complication; Spine Surgery; Site Infection; Surgical Site Infection; Spinal Instrumentation; Index Spinal Instrumentation; Layer-by-Layer Closure; Locoregional Flap-Based Closure |
Rhode Island Hospital |
2024-10-01 | |
| NCT06439953 | RECRUITING | Post-Op Complication; Spine Surgery; Site Infection; Surgical Site Infection; Spinal Instrumentation; Index Spinal Instrumentation; Layer-by-Layer Closure; Locoregional Flap-Based Closure |
Rhode Island Hospital |
2024-10-01 | |
| NCT06747611 | RECRUITING | Alopecia Areata; Alopecia Totalis; Alopecia Universalis |
University of Minnesota |
2025-08-21 | PHASE2 |
| NCT06747611 | RECRUITING | Alopecia Areata; Alopecia Totalis; Alopecia Universalis |
University of Minnesota |
2025-08-21 | PHASE2 |
| NCT05690048 | RECRUITING | Immunotherapy; HCC - Hepatocellular Carcinoma |
Michael Dill |
2025-07-16 | PHASE2 |
| NCT05690048 | RECRUITING | Immunotherapy; HCC - Hepatocellular Carcinoma |
Michael Dill |
2025-07-16 | PHASE2 |
| NCT05461651 | RECRUITING | Infection |
Centre of Postgraduate Medical Education |
2021-09-01 | |
| NCT05461651 | RECRUITING | Infection |
Centre of Postgraduate Medical Education |
2021-09-01 | |
| NCT07201987 | NOT_YET_RECRUITING | Spine Surgery; Postoperative Pain Management |
Ganesh M. Shankar |
2027-01-01 | PHASE2 |
| NCT07201987 | NOT_YET_RECRUITING | Spine Surgery; Postoperative Pain Management |
Ganesh M. Shankar |
2027-01-01 | PHASE2 |
| NCT04729322 | ACTIVE_NOT_RECRUITING | Metastatic Colorectal Adenocarcinoma; Metastatic Small Intestinal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2021-02-22 | PHASE2 |
| NCT04729322 | ACTIVE_NOT_RECRUITING | Metastatic Colorectal Adenocarcinoma; Metastatic Small Intestinal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Small Intestinal Adenocarcinoma AJCC v8; Stage IVA Colorectal Cancer AJCC v8; Stage IVB Colorectal Cancer AJCC v8; Stage IVC Colorectal Cancer AJCC v8 |
M.D. Anderson Cancer Center |
2021-02-22 | PHASE2 |
| NCT07221708 | WITHDRAWN | Clostridioides Difficile; Vancomycin Resistance Enterococcus Faecium |
University of Maryland, Baltimore |
2027-01-01 | PHASE2; PHASE3 |
| NCT07221708 | WITHDRAWN | Clostridioides Difficile; Vancomycin Resistance Enterococcus Faecium |
University of Maryland, Baltimore |
2027-01-01 | PHASE2; PHASE3 |
| NCT03546829 | RECRUITING | Early Stage Non-Small Cell Lung Cancer |
Abramson Cancer Center at Penn Medicine |
2019-03-05 | PHASE1 |
| NCT03546829 | RECRUITING | Early Stage Non-Small Cell Lung Cancer |
Abramson Cancer Center at Penn Medicine |
2019-03-05 | PHASE1 |
| NCT06647277 | NOT_YET_RECRUITING | Parkinson Disease |
ProgenaBiome |
2026-07 | PHASE1 |
| NCT06647277 | NOT_YET_RECRUITING | Parkinson Disease |
ProgenaBiome |
2026-07 | PHASE1 |
| NCT06148025 | RECRUITING | Vaccine Response Impaired |
South Australian Health and Medical Research Institute |
2023-11-23 | PHASE4 |
| NCT06148025 | RECRUITING | Vaccine Response Impaired |
South Australian Health and Medical Research Institute |
2023-11-23 | PHASE4 |
| NCT07220967 | RECRUITING | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2025-10-21 | PHASE4 |
| NCT07220967 | RECRUITING | Breast Cancer |
Memorial Sloan Kettering Cancer Center |
2025-10-21 | PHASE4 |
| NCT03883022 | RECRUITING | Spinal Fusion; Spinal Stenosis; Spondylolisthesis |
Taipei Veterans General Hospital, Taiwan |
2018-09-03 | |
| NCT03883022 | RECRUITING | Spinal Fusion; Spinal Stenosis; Spondylolisthesis |
Taipei Veterans General Hospital, Taiwan |
2018-09-03 | |
| NCT06772675 | RECRUITING | Antibiotic Stewardship; Neonatal Sepsis, Late-Onset; Vancomycin |
Children's Hospital of Philadelphia |
2025-06-02 | |
| NCT06772675 | RECRUITING | Antibiotic Stewardship; Neonatal Sepsis, Late-Onset; Vancomycin |
Children's Hospital of Philadelphia |
2025-06-02 | |
| NCT07490054 | RECRUITING | Chronic Heart Failure |
Melana Yuzefpolskaya, MD |
2025-09-01 | PHASE1 |
| NCT07490054 | RECRUITING | Chronic Heart Failure |
Melana Yuzefpolskaya, MD |
2025-09-01 | PHASE1 |
| NCT05777603 | RECRUITING | Advanced Non Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2024-04-18 | PHASE1 |
| NCT05777603 | RECRUITING | Advanced Non Small Cell Lung Cancer |
National Cancer Institute (NCI) |
2024-04-18 | PHASE1 |
| NCT07605806 | RECRUITING | Healthy Volunteer; Hypersensitivity Reactions; Vancomycin |
Johns Hopkins University |
2026-05-21 | PHASE1; PHASE2 |
| NCT07605806 | RECRUITING | Healthy Volunteer; Hypersensitivity Reactions; Vancomycin |
Johns Hopkins University |
2026-05-21 | PHASE1; PHASE2 |
| NCT07084129 | RECRUITING | Sepsis |
Children's Hospital of Philadelphia |
2026-04-15 | PHASE1 |
| NCT07084129 | RECRUITING | Sepsis |
Children's Hospital of Philadelphia |
2026-04-15 | PHASE1 |
| NCT07633418 | NOT_YET_RECRUITING | Total Knee Arthroplasty |
University of California, San Diego |
2026-06-01 | PHASE4 |
| NCT07633418 | NOT_YET_RECRUITING | Total Knee Arthroplasty |
University of California, San Diego |
2026-06-01 | PHASE4 |
| NCT05266807 | RECRUITING | Clostridioides Difficile Infection |
Benoit Guery |
2023-03-15 | PHASE3 |
| NCT05266807 | RECRUITING | Clostridioides Difficile Infection |
Benoit Guery |
2023-03-15 | PHASE3 |
| NCT07495150 | NOT_YET_RECRUITING | Blood-Brain Barrier; Bacterial Meningitis |
yilong Wang |
2026-04-01 | |
| NCT07495150 | NOT_YET_RECRUITING | Blood-Brain Barrier; Bacterial Meningitis |
yilong Wang |
2026-04-01 | |
| NCT06384651 | RECRUITING | Infections; Ankle Arthritis |
The Methodist Hospital Research Institute |
2024-12-03 | PHASE4 |
| NCT06384651 | RECRUITING | Infections; Ankle Arthritis |
The Methodist Hospital Research Institute |
2024-12-03 | PHASE4 |
| NCT03839914 | ACTIVE_NOT_RECRUITING | Spinal Deformity; Trauma; Spinal Tumor; Surgical Site Infection |
The University of Hong Kong |
2020-08-01 | |
| NCT03839914 | ACTIVE_NOT_RECRUITING | Spinal Deformity; Trauma; Spinal Tumor; Surgical Site Infection |
The University of Hong Kong |
2020-08-01 | |
| NCT06197308 | RECRUITING | Primary Sclerosing Cholangitis |
University of Minnesota |
2024-03-01 | EARLY_PHASE1 |
| NCT06197308 | RECRUITING | Primary Sclerosing Cholangitis |
University of Minnesota |
2024-03-01 | EARLY_PHASE1 |
| NCT06373640 | NOT_YET_RECRUITING | Subarachnoid Hemorrhage |
University Hospital Southampton NHS Foundation Trust |
2024-11 | |
| NCT06373640 | NOT_YET_RECRUITING | Subarachnoid Hemorrhage |
University Hospital Southampton NHS Foundation Trust |
2024-11 | |
| NCT03713528 | ENROLLING_BY_INVITATION | Joint Infection |
OrthoCarolina Research Institute, Inc. |
2020-01-14 | PHASE4 |
| NCT03713528 | ENROLLING_BY_INVITATION | Joint Infection |
OrthoCarolina Research Institute, Inc. |
2020-01-14 | PHASE4 |
| NCT05766670 | RECRUITING | Open tíbia Fracture; Osteomyelitis Tibia; Tibial Fractures |
Wake Forest University Health Sciences |
2024-04-08 | PHASE3 |
| NCT05766670 | RECRUITING | Open tíbia Fracture; Osteomyelitis Tibia; Tibial Fractures |
Wake Forest University Health Sciences |
2024-04-08 | PHASE3 |
| NCT06637332 | RECRUITING | Staphylococcus Aureus Septicemia; Staphylococcus Aureus Bacteremia; S. Aureus Bacteremia; S. Aureus Bloodstream Infection; Staphylococcus Aureus Endocarditis |
Todd C. Lee MD MPH FIDSA |
2024-11-14 | PHASE4 |
| NCT06637332 | RECRUITING | Staphylococcus Aureus Septicemia; Staphylococcus Aureus Bacteremia; S. Aureus Bacteremia; S. Aureus Bloodstream Infection; Staphylococcus Aureus Endocarditis |
Todd C. Lee MD MPH FIDSA |
2024-11-14 | PHASE4 |
| NCT07221370 | RECRUITING | Clostridium Difficile Infection; Vancomycin Resistant Enterococci Infection |
Riverside University Health System Medical Center |
2024-10-21 | PHASE2; PHASE3 |
| NCT07221370 | RECRUITING | Clostridium Difficile Infection; Vancomycin Resistant Enterococci Infection |
Riverside University Health System Medical Center |
2024-10-21 | PHASE2; PHASE3 |
| NCT07282782 | RECRUITING | Total Knee Arthroplasty |
University of California, San Diego |
2024-06-10 | PHASE4 |
| NCT07282782 | RECRUITING | Total Knee Arthroplasty |
University of California, San Diego |
2024-06-10 | PHASE4 |
| NCT07659886 | NOT_YET_RECRUITING | Open Fracture |
Atlantic Health System |
2026-06-10 | PHASE3 |
| NCT07659886 | NOT_YET_RECRUITING | Open Fracture |
Atlantic Health System |
2026-06-10 | PHASE3 |
| NCT04630847 | NOT_YET_RECRUITING | Autism; Autism Spectrum Disorder |
ProgenaBiome |
2025-12 | PHASE1 |
| NCT05770622 | RECRUITING | Sepsis; Infections; Bacteremia |
Murdoch Childrens Research Institute |
2024-11-10 | PHASE4 |
| NCT05770622 | RECRUITING | Sepsis; Infections; Bacteremia |
Murdoch Childrens Research Institute |
2024-11-10 | PHASE4 |
| NCT07341282 | NOT_YET_RECRUITING | Ulcerative Colitis (UC); Primary Sclerosing Cholangitis (PSC) |
McMaster University |
2026-01 | PHASE2 |
| NCT07341282 | NOT_YET_RECRUITING | Ulcerative Colitis (UC); Primary Sclerosing Cholangitis (PSC) |
McMaster University |
2026-01 | PHASE2 |
| NCT04630847 | NOT_YET_RECRUITING | Autism; Autism Spectrum Disorder |
ProgenaBiome |
2025-12 | PHASE1 |
| NCT07300553 | RECRUITING | IBD; Crohn Disease; Ulcerative Colitis (UC) |
Assistance Publique - Hôpitaux de Paris |
2026-01-02 | PHASE2 |
| NCT07300553 | RECRUITING | IBD; Crohn Disease; Ulcerative Colitis (UC) |
Assistance Publique - Hôpitaux de Paris |
2026-01-02 | PHASE2 |
| NCT07525089 | ENROLLING_BY_INVITATION | VRE Colonization; CRE Colonization |
BioMe Inc. |
2026-03-23 | |
| NCT07525089 | ENROLLING_BY_INVITATION | VRE Colonization; CRE Colonization |
BioMe Inc. |
2026-03-23 | |
| NCT04731025 | ACTIVE_NOT_RECRUITING | Implant Complication; Implant Infection; Implant Site Infection; Implant Capsular Contracture; Implant Site Pocket Infection; Implant Expulsion; Antibiotic Side Effect |
Mikkel Herly |
2021-01-27 | PHASE3 |
| NCT04731025 | ACTIVE_NOT_RECRUITING | Implant Complication; Implant Infection; Implant Site Infection; Implant Capsular Contracture; Implant Site Pocket Infection; Implant Expulsion; Antibiotic Side Effect |
Mikkel Herly |
2021-01-27 | PHASE3 |
| NCT07207434 | RECRUITING | Environmental Enteric Dysfunction (EED); Stunting |
Aga Khan University |
2025-08-30 | PHASE2 |
| NCT07207434 | RECRUITING | Environmental Enteric Dysfunction (EED); Stunting |
Aga Khan University |
2025-08-30 | PHASE2 |
| NCT06889701 | RECRUITING | Periprosthetic Joint Infection (PJI) |
TenNor Therapeutics Inc. |
2025-04-03 | PHASE1; PHASE2 |
| NCT06889701 | RECRUITING | Periprosthetic Joint Infection (PJI) |
TenNor Therapeutics Inc. |
2025-04-03 | PHASE1; PHASE2 |
| NCT04401553 | WITHDRAWN | Surgical Site Infection; Beta-lactam Allergy |
University of Texas Southwestern Medical Center |
2024-08-16 | PHASE4 |
| NCT04401553 | WITHDRAWN | Surgical Site Infection; Beta-lactam Allergy |
University of Texas Southwestern Medical Center |
2024-08-16 | PHASE4 |
| NCT06189885 | UNKNOWN | Periprosthetic Joint Infection |
Chang Gung Memorial Hospital |
2024-08-01 | |
| NCT06189885 | UNKNOWN | Periprosthetic Joint Infection |
Chang Gung Memorial Hospital |
2024-08-01 | |
| NCT07267013 | RECRUITING | Aortic Surgery; Extracorporeal Circulation |
Nantes University Hospital |
2026-04-21 | PHASE2 |
| NCT07267013 | RECRUITING | Aortic Surgery; Extracorporeal Circulation |
Nantes University Hospital |
2026-04-21 | PHASE2 |
| NCT07134790 | RECRUITING | Environmental Enteric Dysfunction (EED) |
University Ghent |
2025-07-30 | PHASE2 |
| NCT07134790 | RECRUITING | Environmental Enteric Dysfunction (EED) |
University Ghent |
2025-07-30 | PHASE2 |
| NCT06702345 | NOT_YET_RECRUITING | C. Difficile; C. Difficile Infection; Controlled Human Infection |
Leiden University Medical Center |
2025-03-01 | |
| NCT06702345 | NOT_YET_RECRUITING | C. Difficile; C. Difficile Infection; Controlled Human Infection |
Leiden University Medical Center |
2025-03-01 | |
| NCT06426836 | RECRUITING | Pharmacokinetics; Amoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem; Cefazolin; Teicoplanin; Vancomycin; Ciprofloxacin; Amikacin |
University Hospital, Ghent |
2016-08-19 | |
| NCT06426836 | RECRUITING | Pharmacokinetics; Amoxicillin-clavulanate; Piperacillin-tazobactam; Meropenem; Cefazolin; Teicoplanin; Vancomycin; Ciprofloxacin; Amikacin |
University Hospital, Ghent |
2016-08-19 | |
| NCT03765567 | RECRUITING | Open Fracture |
The University of Texas Health Science Center at San Antonio |
2020-10-05 | PHASE4 |
| NCT03765567 | RECRUITING | Open Fracture |
The University of Texas Health Science Center at San Antonio |
2020-10-05 | PHASE4 |
| NCT07013552 | NOT_YET_RECRUITING | Cardiac Implantable Electronic Device Infections; Infective Endocarditis; Multidrug-resistant Bacteria Screening; Gram Positive Bacterial Infection; Antibiotic Resistant Strain; Antibiotic Therapy; Healthcare Associated Infections |
Medical University of Silesia |
2025-06 | |
| NCT07013552 | NOT_YET_RECRUITING | Cardiac Implantable Electronic Device Infections; Infective Endocarditis; Multidrug-resistant Bacteria Screening; Gram Positive Bacterial Infection; Antibiotic Resistant Strain; Antibiotic Therapy; Healthcare Associated Infections |
Medical University of Silesia |
2025-06 | |
| NCT06126731 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Institute of Cancer Research, United Kingdom |
2023-11-02 | PHASE1; PHASE2 |
| NCT06126731 | RECRUITING | Metastatic Castration-Resistant Prostate Cancer (mCRPC) |
Institute of Cancer Research, United Kingdom |
2023-11-02 | PHASE1; PHASE2 |
| NCT07338773 | COMPLETED | Diabetic Foot Disease; Diabetic Foot Infection; Diabetic Amputation Foot Wound |
Başakşehir Çam & Sakura City Hospital |
2025-08-06 | PHASE4 |
| NCT07338773 | COMPLETED | Diabetic Foot Disease; Diabetic Foot Infection; Diabetic Amputation Foot Wound |
Başakşehir Çam & Sakura City Hospital |
2025-08-06 | PHASE4 |
| NCT04017468 | COMPLETED | Surgical Site Infection |
Insel Gruppe AG, University Hospital Bern |
2019-10-15 | PHASE2 |
| NCT04017468 | COMPLETED | Surgical Site Infection |
Insel Gruppe AG, University Hospital Bern |
2019-10-15 | PHASE2 |
| NCT05876182 | RECRUITING | Primary Sclerosing Cholangitis; Liver and Intrahepatic Bile Duct Disorder; IBD |
University of Milano Bicocca |
2023-06-15 | PHASE2 |
| NCT05876182 | RECRUITING | Primary Sclerosing Cholangitis; Liver and Intrahepatic Bile Duct Disorder; IBD |
University of Milano Bicocca |
2023-06-15 | PHASE2 |
| NCT05975671 | RECRUITING | Sepsis; Sepsis Mrsa; Sepsis Bacteremia; Antimicrobial - Induced Nephropathy; Sepsis, Severe; Septic Shock; Septic Syndrome |
Children's Hospital of Philadelphia |
2023-08-21 | |
| NCT05975671 | RECRUITING | Sepsis; Sepsis Mrsa; Sepsis Bacteremia; Antimicrobial - Induced Nephropathy; Sepsis, Severe; Septic Shock; Septic Syndrome |
Children's Hospital of Philadelphia |
2023-08-21 | |
| NCT06601257 | COMPLETED | Pharmacokinetics and Pharmacodynamics |
University of Michigan |
2025-04-01 | PHASE1 |
| NCT06601257 | COMPLETED | Pharmacokinetics and Pharmacodynamics |
University of Michigan |
2025-04-01 | PHASE1 |
| NCT06817031 | ENROLLING_BY_INVITATION | Environmental Enteric Dysfunction |
International Centre for Diarrhoeal Disease Research, Bangladesh |
2025-04-20 | PHASE2 |
| NCT06817031 | ENROLLING_BY_INVITATION | Environmental Enteric Dysfunction |
International Centre for Diarrhoeal Disease Research, Bangladesh |
2025-04-20 | PHASE2 |
| NCT05539729 | RECRUITING | Multiple Sclerosis |
Icahn School of Medicine at Mount Sinai |
2023-01-31 | PHASE1 |
| NCT05539729 | RECRUITING | Multiple Sclerosis |
Icahn School of Medicine at Mount Sinai |
2023-01-31 | PHASE1 |
| NCT06582264 | COMPLETED | Ulcerative Colitis |
Microbiotica Ltd |
2024-09-27 | PHASE1 |
| NCT06582264 | COMPLETED | Ulcerative Colitis |
Microbiotica Ltd |
2024-09-27 | PHASE1 |
| NCT04399642 | ACTIVE_NOT_RECRUITING | Infection |
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal |
2019-07-05 | |
| NCT04399642 | ACTIVE_NOT_RECRUITING | Infection |
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal |
2019-07-05 | |
| NCT05959603 | RECRUITING | Infection |
Rabin Medical Center |
2020-05-31 | PHASE3 |
| NCT05959603 | RECRUITING | Infection |
Rabin Medical Center |
2020-05-31 | PHASE3 |
| NCT05709184 | UNKNOWN | Clostridioides Difficile Infection |
Rambam Health Care Campus |
2023-11-15 | |
| NCT05709184 | UNKNOWN | Clostridioides Difficile Infection |
Rambam Health Care Campus |
2023-11-15 | |
| NCT05964114 | UNKNOWN | Vancomycin; Pharmacokinetics |
Erasmus Medical Center |
2023-10 | |
| NCT07315438 | COMPLETED | Model Informed Precision Dosing |
Hacettepe University |
2023-12-01 | |
| NCT07315438 | COMPLETED | Model Informed Precision Dosing |
Hacettepe University |
2023-12-01 | |
| NCT05370885 | TERMINATED | Ulcerative Colitis; Colitis, Ulcerative |
Vedanta Biosciences, Inc. |
2023-05-08 | PHASE2 |
| NCT05370885 | TERMINATED | Ulcerative Colitis; Colitis, Ulcerative |
Vedanta Biosciences, Inc. |
2023-05-08 | PHASE2 |
| NCT06543940 | RECRUITING | AKI - Acute Kidney Injury |
Mahidol University |
2024-09-01 | |
| NCT06543940 | RECRUITING | AKI - Acute Kidney Injury |
Mahidol University |
2024-09-01 | |
| NCT06651268 | UNKNOWN | Wound Complication; Cardiac Surgery |
Liaquat National Hospital & Medical College |
2024-11-01 | PHASE1; PHASE2 |
| NCT06651268 | UNKNOWN | Wound Complication; Cardiac Surgery |
Liaquat National Hospital & Medical College |
2024-11-01 | PHASE1; PHASE2 |
| NCT06503978 | ACTIVE_NOT_RECRUITING | Autism Spectrum Disorder; Gastro-Intestinal Disorder; Constipation; Diarrhea |
Gut-Brain-Axis Therapeutics Inc. |
2024-08-20 | PHASE2 |
| NCT06503978 | ACTIVE_NOT_RECRUITING | Autism Spectrum Disorder; Gastro-Intestinal Disorder; Constipation; Diarrhea |
Gut-Brain-Axis Therapeutics Inc. |
2024-08-20 | PHASE2 |
| NCT05823116 | COMPLETED | Vancomycin |
Aaron Cook |
2023-05-22 | PHASE4 |
| NCT05823116 | COMPLETED | Vancomycin |
Aaron Cook |
2023-05-22 | PHASE4 |
| NCT06716749 | COMPLETED | Primary Total Knee Arthroplasty; Intraosseous Morphine Injection; Knee Osteoarthritis |
Carilion Clinic |
2024-12-01 | PHASE2 |
| NCT06716749 | COMPLETED | Primary Total Knee Arthroplasty; Intraosseous Morphine Injection; Knee Osteoarthritis |
Carilion Clinic |
2024-12-01 | PHASE2 |
| NCT06336824 | UNKNOWN | Staphylococcus Aureus Bacteremia |
Clinical Research Centre, Malaysia |
2024-06-28 | PHASE3 |
| NCT06336824 | UNKNOWN | Staphylococcus Aureus Bacteremia |
Clinical Research Centre, Malaysia |
2024-06-28 | PHASE3 |
| NCT04500275 | COMPLETED | Sternal Wound Infection |
National Cheng-Kung University Hospital |
2020-07-01 | PHASE4 |
| NCT04500275 | COMPLETED | Sternal Wound Infection |
National Cheng-Kung University Hospital |
2020-07-01 | PHASE4 |
| NCT02285140 | TERMINATED | Thoracic Surgery; Antibiotic Prophylaxis |
Hamilton Health Sciences Corporation |
2015-04 | |
| NCT02285140 | TERMINATED | Thoracic Surgery; Antibiotic Prophylaxis |
Hamilton Health Sciences Corporation |
2015-04 | |
| NCT03710122 | TERMINATED | Primary Sclerosing Cholangitis |
Elizabeth Carey |
2020-01-23 | PHASE2; PHASE3 |
| NCT03710122 | TERMINATED | Primary Sclerosing Cholangitis |
Elizabeth Carey |
2020-01-23 | PHASE2; PHASE3 |
| NCT04182633 | ACTIVE_NOT_RECRUITING | Autism Spectrum Disorder; Gastro-Intestinal Disorder; Constipation; Diarrhea |
Arizona State University |
2019-11-15 | PHASE2 |
| NCT04182633 | ACTIVE_NOT_RECRUITING | Autism Spectrum Disorder; Gastro-Intestinal Disorder; Constipation; Diarrhea |
Arizona State University |
2019-11-15 | PHASE2 |
| NCT06272994 | COMPLETED | Community-acquired Pneumonia |
Vanderbilt University Medical Center |
2024-04-03 | |
| NCT06272994 | COMPLETED | Community-acquired Pneumonia |
Vanderbilt University Medical Center |
2024-04-03 | |
| NCT06321796 | UNKNOWN | Pitt Hopkins Syndrome |
Gut-Brain-Axis Therapeutics Inc. |
2024-02-27 | PHASE2 |
| NCT06321796 | UNKNOWN | Pitt Hopkins Syndrome |
Gut-Brain-Axis Therapeutics Inc. |
2024-02-27 | PHASE2 |
| NCT07784075 | COMPLETED | Immediate Implant Placement in Chronic Infected Socket |
Al-Azhar University |
2024-07-10 | PHASE1 |
| NCT07784075 | COMPLETED | Immediate Implant Placement in Chronic Infected Socket |
Al-Azhar University |
2024-07-10 | PHASE1 |
| NCT07364435 | COMPLETED | Vancomycin-Resistant Enterococcus |
Özkan Kasap |
2024-09-01 | |
| NCT07364435 | COMPLETED | Vancomycin-Resistant Enterococcus |
Özkan Kasap |
2024-09-01 | |
| NCT02096536 | UNKNOWN | Neonatal Infection |
Universitaire Ziekenhuizen KU Leuven |
2014-04 | PHASE4 |
| NCT02096536 | UNKNOWN | Neonatal Infection |
Universitaire Ziekenhuizen KU Leuven |
2014-04 | PHASE4 |
| NCT05770726 | UNKNOWN | Diarrhea Infectious |
National Cheng-Kung University Hospital |
2023-04-21 | |
| NCT05770726 | UNKNOWN | Diarrhea Infectious |
National Cheng-Kung University Hospital |
2023-04-21 | |
| NCT00945152 | UNKNOWN | Bacterial Infections; Wounds |
Robert S Berman MD |
2011-07-15 | PHASE2 |
| NCT00945152 | UNKNOWN | Bacterial Infections; Wounds |
Robert S Berman MD |
2011-07-15 | PHASE2 |
| NCT05849090 | COMPLETED | Infections |
University of Utah |
2023-03-27 | EARLY_PHASE1 |
| NCT05849090 | COMPLETED | Infections |
University of Utah |
2023-03-27 | EARLY_PHASE1 |
| NCT06166381 | RECRUITING | Infection, Bacterial |
University of Duhok |
2024-01-25 | |
| NCT06166381 | RECRUITING | Infection, Bacterial |
University of Duhok |
2024-01-25 | |
| NCT06161870 | RECRUITING | Severe Infection |
Central South University |
2021-01-01 | PHASE4 |
| NCT06161870 | RECRUITING | Severe Infection |
Central South University |
2021-01-01 | PHASE4 |
| NCT06283433 | UNKNOWN | Infection, Bacterial |
Erasmus Medical Center |
2023-10-25 | |
| NCT06283433 | UNKNOWN | Infection, Bacterial |
Erasmus Medical Center |
2023-10-25 | |
| NCT05156437 | TERMINATED | Endocarditis |
West Virginia University |
2022-03-16 | PHASE4 |
| NCT05156437 | TERMINATED | Endocarditis |
West Virginia University |
2022-03-16 | PHASE4 |
| NCT04138706 | COMPLETED | Clostridium Difficile Infection |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2020-11-19 | PHASE3 |
| NCT04138706 | COMPLETED | Clostridium Difficile Infection |
McGill University Health Centre/Research Institute of the McGill University Health Centre |
2020-11-19 | PHASE3 |
| NCT06527131 | UNKNOWN | Charcot Foot Ulcer |
Cairo University |
2024-07 | |
| NCT06527131 | UNKNOWN | Charcot Foot Ulcer |
Cairo University |
2024-07 | |
| NCT04246151 | WITHDRAWN | Clostridium Difficile Colonization; Clostridium Difficile Diarrhea |
Hamilton Health Sciences Corporation |
2022-09-01 | EARLY_PHASE1 |
| NCT04246151 | WITHDRAWN | Clostridium Difficile Colonization; Clostridium Difficile Diarrhea |
Hamilton Health Sciences Corporation |
2022-09-01 | EARLY_PHASE1 |
| NCT03845790 | COMPLETED | Surgical Site Infection |
Poitiers University Hospital |
2019-05-26 | PHASE1 |
| NCT03845790 | COMPLETED | Surgical Site Infection |
Poitiers University Hospital |
2019-05-26 | PHASE1 |
| NCT02701608 | COMPLETED | Infective Endocarditis |
University Hospital, Tours |
2016-02-29 | PHASE3 |
| NCT02701608 | COMPLETED | Infective Endocarditis |
University Hospital, Tours |
2016-02-29 | PHASE3 |
| NCT02667418 | TERMINATED | Clostridium; Difficile; Fidaxomicin; Vancomycin |
VA Office of Research and Development |
2016-02-19 | PHASE4 |
| NCT02667418 | TERMINATED | Clostridium; Difficile; Fidaxomicin; Vancomycin |
VA Office of Research and Development |
2016-02-19 | PHASE4 |
| NCT04995653 | COMPLETED | Allogeneic Hematopoietic Stem Cell Transplantation |
Seres Therapeutics, Inc. |
2021-11-24 | PHASE1 |
| NCT04995653 | COMPLETED | Allogeneic Hematopoietic Stem Cell Transplantation |
Seres Therapeutics, Inc. |
2021-11-24 | PHASE1 |
| NCT05831774 | ACTIVE_NOT_RECRUITING | Shoulder Injuries |
The Methodist Hospital Research Institute |
2023-06-01 | PHASE4 |
| NCT05831774 | ACTIVE_NOT_RECRUITING | Shoulder Injuries |
The Methodist Hospital Research Institute |
2023-06-01 | PHASE4 |
| NCT05077085 | WITHDRAWN | Clostridium Infections; Clostridioides Difficile; Enterocolitis, Pseudomembranous |
Leiden University Medical Center |
2022-01 | PHASE4 |
| NCT05077085 | WITHDRAWN | Clostridium Infections; Clostridioides Difficile; Enterocolitis, Pseudomembranous |
Leiden University Medical Center |
2022-01 | PHASE4 |
| NCT04856878 | UNKNOWN | Central Line-associated Bloodstream Infection (CLABSI); Catheter-related Bloodstream Infection |
University of Zurich |
2021-06-01 | PHASE4 |
| NCT04856878 | UNKNOWN | Central Line-associated Bloodstream Infection (CLABSI); Catheter-related Bloodstream Infection |
University of Zurich |
2021-06-01 | PHASE4 |
| NCT04948814 | UNKNOWN | Autism Spectrum Disorder |
Tongji Hospital |
2022-06-01 | PHASE1 |
| NCT04948814 | UNKNOWN | Autism Spectrum Disorder |
Tongji Hospital |
2022-06-01 | PHASE1 |
| NCT05256693 | UNKNOWN | Clostridium Difficile Infections; Stem Cell Transplant Complications |
Assistance Publique - Hôpitaux de Paris |
2022-03 | PHASE3 |
| NCT05256693 | UNKNOWN | Clostridium Difficile Infections; Stem Cell Transplant Complications |
Assistance Publique - Hôpitaux de Paris |
2022-03 | PHASE3 |
| NCT05972603 | UNKNOWN | Osteoarthritis, Knee; Osteoarthritis, Hip; Rheumatoid Arthritis; Avascular Necrosis of Hip |
Independent Public Healthcare Center in Rypin |
2022-07-01 | |
| NCT05972603 | UNKNOWN | Osteoarthritis, Knee; Osteoarthritis, Hip; Rheumatoid Arthritis; Avascular Necrosis of Hip |
Independent Public Healthcare Center in Rypin |
2022-07-01 | |
| NCT05693077 | UNKNOWN | Clostridioides Difficile Infection |
Leiden University Medical Center |
2023-09-22 | PHASE1 |
| NCT05693077 | UNKNOWN | Clostridioides Difficile Infection |
Leiden University Medical Center |
2023-09-22 | PHASE1 |
| NCT05607030 | COMPLETED | Prosthetic-joint Infection |
Osteal Therapeutics, Inc. |
2023-01-23 | PHASE2 |
| NCT05607030 | COMPLETED | Prosthetic-joint Infection |
Osteal Therapeutics, Inc. |
2023-01-23 | PHASE2 |
| NCT05697965 | UNKNOWN | Arthroplasty Complications; Periprosthetic Fracture of Hip |
Assiut University |
2023-03-01 | PHASE2 |
| NCT05697965 | UNKNOWN | Arthroplasty Complications; Periprosthetic Fracture of Hip |
Assiut University |
2023-03-01 | PHASE2 |
| NCT05625373 | RECRUITING | Postoperative Complications |
Women and Infants Hospital of Rhode Island |
2022-10-25 | PHASE2; PHASE3 |
| NCT05625373 | RECRUITING | Postoperative Complications |
Women and Infants Hospital of Rhode Island |
2022-10-25 | PHASE2; PHASE3 |
| NCT04781387 | COMPLETED | Clostridioides Difficile Infection |
Crestone, Inc |
2021-01-05 | PHASE2 |
| NCT04781387 | COMPLETED | Clostridioides Difficile Infection |
Crestone, Inc |
2021-01-05 | PHASE2 |
| NCT04911270 | COMPLETED | Gram-Positive Bacterial Infections; Vancomycin; Pharmacokinetics; Pharmacodynamics |
University of Maryland, Baltimore |
2022-05-09 | |
| NCT04911270 | COMPLETED | Gram-Positive Bacterial Infections; Vancomycin; Pharmacokinetics; Pharmacodynamics |
University of Maryland, Baltimore |
2022-05-09 | |
| NCT05079620 | TERMINATED | Aspiration; Aspiration Pneumonia |
UConn Health |
2021-11-30 | PHASE4 |
| NCT05079620 | TERMINATED | Aspiration; Aspiration Pneumonia |
UConn Health |
2021-11-30 | PHASE4 |
| NCT03796650 | TERMINATED | Clostridium Difficile Infection |
Oslo University Hospital |
2019-07-17 | PHASE3 |
| NCT03796650 | TERMINATED | Clostridium Difficile Infection |
Oslo University Hospital |
2019-07-17 | PHASE3 |
| NCT06272994 | Enrolling by invitation | Community-acquired Pneumonia |
Vanderbilt University Medical Center |
2024-04-03 | Not Applicable |
| NCT05320068 | COMPLETED | Clostridioides Difficile Infection |
Julia Orígüen |
2022-08-02 | PHASE3 |
| NCT05320068 | COMPLETED | Clostridioides Difficile Infection |
Julia Orígüen |
2022-08-02 | PHASE3 |
| NCT05276687 | UNKNOWN | Surgical Wound Infection |
Assiut University |
2022-09 | PHASE4 |
| NCT05276687 | UNKNOWN | Surgical Wound Infection |
Assiut University |
2022-09 | PHASE4 |
| NCT05225558 | TERMINATED | MRSA Bacteremia |
LigaChem Biosciences, Inc. |
2022-04-26 | PHASE2 |
| NCT05225558 | TERMINATED | MRSA Bacteremia |
LigaChem Biosciences, Inc. |
2022-04-26 | PHASE2 |
| NCT06050785 | Not yet recruiting | Anterior Cruciate Ligament Injuries |
Assiut University |
2024-02-01 | -- |
| NCT05705843 | UNKNOWN | Infection, Surgical Site |
The Methodist Hospital Research Institute |
2023-01-25 | PHASE4 |
| NCT05705843 | UNKNOWN | Infection, Surgical Site |
The Methodist Hospital Research Institute |
2023-01-25 | PHASE4 |
| NCT04075526 | COMPLETED | Osteoarthritis |
NYU Langone Health |
2019-10-01 | PHASE1 |
| NCT04075526 | COMPLETED | Osteoarthritis |
NYU Langone Health |
2019-10-01 | PHASE1 |
| NCT02814916 | COMPLETED | Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections |
AbbVie |
2017-03-30 | PHASE3 |
| NCT02814916 | COMPLETED | Methicillin-Resistant Staphylococcus Aureus; Bacterial Infections; Staphylococcal Skin Infections |
AbbVie |
2017-03-30 | PHASE3 |
| NCT02590523 | SUSPENDED | Intracameral Antibiotics; Cataract Surgery; Phacoemulsification; Endophthalmitis; Vancomycin; Moxifloxacin |
Panhandle Eye Group, LLP |
2023-01 | PHASE3 |
| NCT02590523 | SUSPENDED | Intracameral Antibiotics; Cataract Surgery; Phacoemulsification; Endophthalmitis; Vancomycin; Moxifloxacin |
Panhandle Eye Group, LLP |
2023-01 | PHASE3 |
| NCT05651464 | UNKNOWN | Catheter-Related Infections |
Universität des Saarlandes |
2023-01-01 | |
| NCT05651464 | UNKNOWN | Catheter-Related Infections |
Universität des Saarlandes |
2023-01-01 | |
| NCT05363462 | COMPLETED | Surgical Site Infection; Complication of Surgical Procedure |
Universidad Autonoma de Nuevo Leon |
2022-01-05 | |
| NCT05363462 | COMPLETED | Surgical Site Infection; Complication of Surgical Procedure |
Universidad Autonoma de Nuevo Leon |
2022-01-05 | |
| NCT04666948 | COMPLETED | Vancomycin |
University Hospital, Ghent |
2020-12-28 | PHASE4 |
| NCT04666948 | COMPLETED | Vancomycin |
University Hospital, Ghent |
2020-12-28 | PHASE4 |
| NCT05535075 | COMPLETED | Vancomycin |
University Hospital, Ghent |
2021-11-12 | PHASE4 |
| NCT05535075 | COMPLETED | Vancomycin |
University Hospital, Ghent |
2021-11-12 | PHASE4 |
| NCT03936998 | RECRUITING | Peanut Allergy |
Massachusetts General Hospital |
2019-06-28 | PHASE1; PHASE2 |
| NCT03936998 | RECRUITING | Peanut Allergy |
Massachusetts General Hospital |
2019-06-28 | PHASE1; PHASE2 |
| NCT04983901 | COMPLETED | Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2021-09-14 | PHASE2 |
| NCT04983901 | COMPLETED | Hematopoietic and Lymphoid Cell Neoplasm; Malignant Solid Neoplasm |
M.D. Anderson Cancer Center |
2021-09-14 | PHASE2 |
| NCT04775953 | COMPLETED | Staphylococcal Bacteraemia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2021-04-22 | PHASE2 |
| NCT04775953 | COMPLETED | Staphylococcal Bacteraemia |
National Institute of Allergy and Infectious Diseases (NIAID) |
2021-04-22 | PHASE2 |
| NCT04247542 | COMPLETED | Clostridium Difficile Infection |
Acurx Pharmaceuticals Inc. |
2020-03-06 | PHASE2 |
| NCT04247542 | COMPLETED | Clostridium Difficile Infection |
Acurx Pharmaceuticals Inc. |
2020-03-06 | PHASE2 |
| NCT05964114 | Not yet recruiting | Vancomycin|Pharmacokinetics |
Erasmus Medical Center |
2023-10 | Not Applicable |
| NCT04872400 | COMPLETED | Fractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone; Extremity Fracture Lower; Extremity Fractures Upper |
University of Colorado, Denver |
2021-06-14 | PHASE4 |
| NCT04872400 | COMPLETED | Fractures, Open; Wounds and Injuries--Infections; Anti-Bacterial Agents; Fractures, Bone; Extremity Fracture Lower; Extremity Fractures Upper |
University of Colorado, Denver |
2021-06-14 | PHASE4 |
| NCT06030219 | COMPLETED | Healthy Volunteers |
University of Houston |
2020-10-12 | PHASE1 |
| NCT06030219 | COMPLETED | Healthy Volunteers |
University of Houston |
2020-10-12 | PHASE1 |
| NCT04816968 | UNKNOWN | Severe Bacterial Infections |
Ospedale San Carlo Borromeo |
2021-09 | PHASE1 |
| NCT04816968 | UNKNOWN | Severe Bacterial Infections |
Ospedale San Carlo Borromeo |
2021-09 | PHASE1 |
| NCT02996487 | COMPLETED | Clostridium Difficile Infection |
Corewell Health East |
2016-12-19 | PHASE4 |
| NCT02996487 | COMPLETED | Clostridium Difficile Infection |
Corewell Health East |
2016-12-19 | PHASE4 |
| NCT03617445 | TERMINATED | Clostridium Difficile Infection Recurrence |
University of Wisconsin, Madison |
2022-08-03 | PHASE2 |
| NCT03617445 | TERMINATED | Clostridium Difficile Infection Recurrence |
University of Wisconsin, Madison |
2022-08-03 | PHASE2 |
| NCT03402945 | COMPLETED | Surgical Site Infections |
Population Health Research Institute |
2018-03-05 | PHASE4 |
| NCT03402945 | COMPLETED | Surgical Site Infections |
Population Health Research Institute |
2018-03-05 | PHASE4 |
| NCT04899115 | COMPLETED | Cirrhosis; Hepatic Encephalopathy |
Patricia Bloom |
2021-08-06 | PHASE2 |
| NCT04899115 | COMPLETED | Cirrhosis; Hepatic Encephalopathy |
Patricia Bloom |
2021-08-06 | PHASE2 |
| NCT04662632 | COMPLETED | Prosthetic Joint Infection |
Osteal Therapeutics, Inc. |
2021-11-01 | PHASE2 |
| NCT04662632 | COMPLETED | Prosthetic Joint Infection |
Osteal Therapeutics, Inc. |
2021-11-01 | PHASE2 |
| NCT03939273 | UNKNOWN | Systemic Inflammatory Response Syndrome; Postoperative Shock; Coronary Artery Disease; Extracorporeal Circulation; Complications |
Radboud University Medical Center |
2022-03 | |
| NCT03939273 | UNKNOWN | Systemic Inflammatory Response Syndrome; Postoperative Shock; Coronary Artery Disease; Extracorporeal Circulation; Complications |
Radboud University Medical Center |
2022-03 | |
| NCT02701595 | COMPLETED | Infective Endocarditis |
University Hospital, Tours |
2016-02-29 | PHASE3 |
| NCT02701595 | COMPLETED | Infective Endocarditis |
University Hospital, Tours |
2016-02-29 | PHASE3 |
| NCT03426761 | COMPLETED | Bone Infection; Osteomyelitis; Septic Arthritis; Joint Infection; Prosthetic Joint Infection |
Infectious Diseases Physicians, Inc. |
2018-01-25 | PHASE4 |
| NCT03426761 | COMPLETED | Bone Infection; Osteomyelitis; Septic Arthritis; Joint Infection; Prosthetic Joint Infection |
Infectious Diseases Physicians, Inc. |
2018-01-25 | PHASE4 |
| NCT05338008 | COMPLETED | Hip |
The Affiliated Hospital of Qingdao University |
2022-05-01 | |
| NCT05338008 | COMPLETED | Hip |
The Affiliated Hospital of Qingdao University |
2022-05-01 | |
| NCT03785210 | TERMINATED | Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis |
National Cancer Institute (NCI) |
2019-06-05 | PHASE2 |
| NCT03785210 | TERMINATED | Hepatocellular Carcinoma; Hepatocellular Cancer; Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer; Liver Metastasis |
National Cancer Institute (NCI) |
2019-06-05 | PHASE2 |
| NCT04648696 | TERMINATED | Infection |
Wake Forest University Health Sciences |
2021-03-03 | PHASE4 |
| NCT04648696 | TERMINATED | Infection |
Wake Forest University Health Sciences |
2021-03-03 | PHASE4 |
| NCT05338021 | COMPLETED | Knee Osteoarthritis |
The Affiliated Hospital of Qingdao University |
2022-05-25 | |
| NCT05338021 | COMPLETED | Knee Osteoarthritis |
The Affiliated Hospital of Qingdao University |
2022-05-25 | |
| NCT03643887 | WITHDRAWN | Clostridium Difficile Infection |
University of Wisconsin, Madison |
2022-09-01 | PHASE2 |
| NCT03643887 | WITHDRAWN | Clostridium Difficile Infection |
University of Wisconsin, Madison |
2022-09-01 | PHASE2 |
| NCT02801656 | WITHDRAWN | Clostridium Difficile |
Memorial University of Newfoundland |
2020-12-01 | PHASE3 |
| NCT02801656 | WITHDRAWN | Clostridium Difficile |
Memorial University of Newfoundland |
2020-12-01 | PHASE3 |
| NCT04968951 | TERMINATED | Ulcerative Colitis; FMT; Fecal Microbiota Transplant |
Ari M Grinspan |
2021-11-10 | EARLY_PHASE1 |
| NCT04968951 | TERMINATED | Ulcerative Colitis; FMT; Fecal Microbiota Transplant |
Ari M Grinspan |
2021-11-10 | EARLY_PHASE1 |
| NCT04673877 | COMPLETED | Infection; Hand Injury Wrist; Hand Injuries; Hand Injuries and Disorders; Hand Arthritis |
Mayo Clinic |
2021-08-26 | PHASE1 |
| NCT04673877 | COMPLETED | Infection; Hand Injury Wrist; Hand Injuries; Hand Injuries and Disorders; Hand Arthritis |
Mayo Clinic |
2021-08-26 | PHASE1 |
| NCT03479710 | COMPLETED | Antimicrobial Resistance; Colonization |
Chinese University of Hong Kong |
2018-02-10 | PHASE2 |
| NCT03479710 | COMPLETED | Antimicrobial Resistance; Colonization |
Chinese University of Hong Kong |
2018-02-10 | PHASE2 |
| NCT04000555 | TERMINATED | Clostridium Difficile Infection; Clostridium Difficile Infection Recurrence |
University of South Florida |
2019-09-01 | PHASE4 |
| NCT04000555 | TERMINATED | Clostridium Difficile Infection; Clostridium Difficile Infection Recurrence |
University of South Florida |
2019-09-01 | PHASE4 |
| NCT03557008 | COMPLETED | Rabies Human |
Emory University |
2018-07-05 | PHASE4 |
| NCT03557008 | COMPLETED | Rabies Human |
Emory University |
2018-07-05 | PHASE4 |
| NCT07001527 | COMPLETED | Chlorhexidine |
Hospital Universitario Evangelico de Curitiba |
2022-06-01 | PHASE3 |
| NCT07001527 | COMPLETED | Chlorhexidine |
Hospital Universitario Evangelico de Curitiba |
2022-06-01 | PHASE3 |
| NCT04088305 | COMPLETED | Pneumonia, Staphylococcal |
Peking University Third Hospital |
2019-10-01 | PHASE4 |
| NCT04088305 | COMPLETED | Pneumonia, Staphylococcal |
Peking University Third Hospital |
2019-10-01 | PHASE4 |
| NCT04042233 | COMPLETED | Prosthetic Joint Infection; Vancomycin; Joint Diseases |
The Methodist Hospital Research Institute |
2019-12-31 | PHASE4 |
| NCT04042233 | COMPLETED | Prosthetic Joint Infection; Vancomycin; Joint Diseases |
The Methodist Hospital Research Institute |
2019-12-31 | PHASE4 |
| NCT04917627 | UNKNOWN | Wound Infection |
Hamad General Hospital |
2021-05-01 | PHASE4 |
| NCT04917627 | UNKNOWN | Wound Infection |
Hamad General Hospital |
2021-05-01 | PHASE4 |
| NCT03408886 | ACTIVE_NOT_RECRUITING | Autism Spectrum Disorder; Gastrointestinal Disorder |
Arizona State University |
2018-01-04 | PHASE2 |
| NCT03408886 | ACTIVE_NOT_RECRUITING | Autism Spectrum Disorder; Gastrointestinal Disorder |
Arizona State University |
2018-01-04 | PHASE2 |
| NCT04839653 | UNKNOWN | Pneumonia, Ventilator-Associated; Pneumonia; Bloodstream Infection; Sepsis; Respiratory Distress Syndrome; Respiratory Tract Infections; Critical Illness |
MEDSI Clinical Hospital 1, ICU |
2021-05-01 | |
| NCT04839653 | UNKNOWN | Pneumonia, Ventilator-Associated; Pneumonia; Bloodstream Infection; Sepsis; Respiratory Distress Syndrome; Respiratory Tract Infections; Critical Illness |
MEDSI Clinical Hospital 1, ICU |
2021-05-01 | |
| NCT04132427 | COMPLETED | Pitt Hopkins Syndrome |
Arizona State University |
2019-09-30 | PHASE2 |
| NCT04132427 | COMPLETED | Pitt Hopkins Syndrome |
Arizona State University |
2019-09-30 | PHASE2 |
| NCT03817125 | COMPLETED | Metastatic Melanoma |
Parker Institute for Cancer Immunotherapy |
2019-01-28 | PHASE1 |
| NCT03817125 | COMPLETED | Metastatic Melanoma |
Parker Institute for Cancer Immunotherapy |
2019-01-28 | PHASE1 |
| NCT03466502 | COMPLETED | Clostridium Difficile Infection |
University of Nevada, Reno |
2018-03-08 | PHASE4 |
| NCT03466502 | COMPLETED | Clostridium Difficile Infection |
University of Nevada, Reno |
2018-03-08 | PHASE4 |
| NCT04025567 | WITHDRAWN | Metastatic Hepatocellular Carcinoma; Hepatocellular Carcinoma |
National Cancer Institute (NCI) |
2020-03-12 | PHASE2 |
| NCT04025567 | WITHDRAWN | Metastatic Hepatocellular Carcinoma; Hepatocellular Carcinoma |
National Cancer Institute (NCI) |
2020-03-12 | PHASE2 |
| NCT01509339 | WITHDRAWN | Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus |
Case Western Reserve University |
2012-01 | PHASE1 |
| NCT01509339 | WITHDRAWN | Cystic Fibrosis; Methicillin-resistant Staphylococcus Aureus |
Case Western Reserve University |
2012-01 | PHASE1 |
| NCT02663596 | UNKNOWN | Pediatric Continuous Renal Replacement Therapy; Dialysis; Renal Failure |
Drexel University |
2017-01 | PHASE1 |
| NCT02663596 | UNKNOWN | Pediatric Continuous Renal Replacement Therapy; Dialysis; Renal Failure |
Drexel University |
2017-01 | PHASE1 |
| NCT02686645 | UNKNOWN | Clostridium Difficile Infection |
Queen Elizabeth II Health Sciences Centre |
2016-12 | PHASE2; PHASE3 |
| NCT02686645 | UNKNOWN | Clostridium Difficile Infection |
Queen Elizabeth II Health Sciences Centre |
2016-12 | PHASE2; PHASE3 |
| NCT03880539 | COMPLETED | Clostridium Difficile Infection Recurrence |
University of Kansas Medical Center |
2019-06-25 | PHASE4 |
| NCT03880539 | COMPLETED | Clostridium Difficile Infection Recurrence |
University of Kansas Medical Center |
2019-06-25 | PHASE4 |
| NCT03595553 | COMPLETED | Clostridioides Difficile Infection |
Summit Therapeutics |
2019-01-28 | PHASE3 |
| NCT03595553 | COMPLETED | Clostridioides Difficile Infection |
Summit Therapeutics |
2019-01-28 | PHASE3 |
| NCT03560700 | COMPLETED | VRE Colonization |
Hvidovre University Hospital |
2018-06-07 | |
| NCT03560700 | COMPLETED | VRE Colonization |
Hvidovre University Hospital |
2018-06-07 | |
| NCT04758442 | UNKNOWN | Vancomycin; Hematologic Malignancies; Febrile Neutropenia |
Ciusss de L'Est de l'Île de Montréal |
2021-02-01 | |
| NCT04758442 | UNKNOWN | Vancomycin; Hematologic Malignancies; Febrile Neutropenia |
Ciusss de L'Est de l'Île de Montréal |
2021-02-01 | |
| NCT05535725 | COMPLETED | Surgical Site Infection |
Clinique Ortos |
2019-10-10 | PHASE4 |
| NCT05535725 | COMPLETED | Surgical Site Infection |
Clinique Ortos |
2019-10-10 | PHASE4 |
| NCT04802837 | TERMINATED | Clostridioides Difficile Infection |
Summit Therapeutics |
2021-05-19 | PHASE3 |
| NCT04802837 | TERMINATED | Clostridioides Difficile Infection |
Summit Therapeutics |
2021-05-19 | PHASE3 |
| NCT03221023 | UNKNOWN | Vancomycin; Implantable Neural Stimulator; Deep Brain Stimulation; Surgical Site Infection |
University of British Columbia |
2017-09-15 | PHASE2; PHASE3 |
| NCT03221023 | UNKNOWN | Vancomycin; Implantable Neural Stimulator; Deep Brain Stimulation; Surgical Site Infection |
University of British Columbia |
2017-09-15 | PHASE2; PHASE3 |
| NCT04756895 | COMPLETED | Vancomycin; Adult; Area Under Curve |
CR-CSSS Champlain-Charles-Le Moyne |
2021-03-01 | |
| NCT04756895 | COMPLETED | Vancomycin; Adult; Area Under Curve |
CR-CSSS Champlain-Charles-Le Moyne |
2021-03-01 | |
| NCT03827447 | COMPLETED | Clostridium Difficile Infection |
Medical College of Wisconsin |
2019-07-17 | PHASE1 |
| NCT03827447 | COMPLETED | Clostridium Difficile Infection |
Medical College of Wisconsin |
2019-07-17 | PHASE1 |
| NCT03759041 | TERMINATED | Ulcerative Colitis |
Seres Therapeutics, Inc. |
2018-12-19 | PHASE2 |
| NCT03759041 | TERMINATED | Ulcerative Colitis |
Seres Therapeutics, Inc. |
2018-12-19 | PHASE2 |
| NCT02692651 | COMPLETED | Clostridium Difficile Infection (CDI) |
University of Michigan |
2017-05-01 | PHASE4 |
| NCT02692651 | COMPLETED | Clostridium Difficile Infection (CDI) |
University of Michigan |
2017-05-01 | PHASE4 |
| NCT04297176 | COMPLETED | Infection, Bacterial |
Hamad Medical Corporation |
2020-01-23 | |
| NCT04297176 | COMPLETED | Infection, Bacterial |
Hamad Medical Corporation |
2020-01-23 | |
| NCT04238923 | UNKNOWN | Vascular Diseases; Peripheral Vascular Disease; Surgical Site Infection; Bypass Complication |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2020-05-01 | PHASE2; PHASE3 |
| NCT03485950 | COMPLETED | Other Infectious Diseases |
M.D. Anderson Cancer Center |
2018-05-16 | PHASE2 |
| NCT04238923 | UNKNOWN | Vascular Diseases; Peripheral Vascular Disease; Surgical Site Infection; Bypass Complication |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2020-05-01 | PHASE2; PHASE3 |
| NCT03485950 | COMPLETED | Other Infectious Diseases |
M.D. Anderson Cancer Center |
2018-05-16 | PHASE2 |
| NCT03200093 | TERMINATED | Clostridium Difficile Infection |
Rochester General Hospital |
2017-06-08 | PHASE4 |
| NCT03200093 | TERMINATED | Clostridium Difficile Infection |
Rochester General Hospital |
2017-06-08 | PHASE4 |
| NCT02641236 | COMPLETED | Hematopoietic Stem Cell Transplantation (HSCT); Acute GVH Disease |
Dana-Farber Cancer Institute |
2016-03 | PHASE2 |
| NCT02641236 | COMPLETED | Hematopoietic Stem Cell Transplantation (HSCT); Acute GVH Disease |
Dana-Farber Cancer Institute |
2016-03 | PHASE2 |
| NCT02216227 | COMPLETED | Surgical Site Infection |
VA Office of Research and Development |
2014-04-01 | |
| NCT02216227 | COMPLETED | Surgical Site Infection |
VA Office of Research and Development |
2014-04-01 | |
| NCT03673956 | COMPLETED | Chronic Rhinosinusitis (Diagnosis) |
Mayo Clinic |
2018-09-26 | PHASE1; PHASE2 |
| NCT03673956 | COMPLETED | Chronic Rhinosinusitis (Diagnosis) |
Mayo Clinic |
2018-09-26 | PHASE1; PHASE2 |
| NCT03388268 | COMPLETED | Clostridium Difficile Infection; Diarrhea |
Washington University School of Medicine |
2017-12-29 | PHASE4 |
| NCT03388268 | COMPLETED | Clostridium Difficile Infection; Diarrhea |
Washington University School of Medicine |
2017-12-29 | PHASE4 |
| NCT02764359 | UNKNOWN | Infection; Sepsis; Obesity |
CAMC Health System |
2016-08-01 | |
| NCT02764359 | UNKNOWN | Infection; Sepsis; Obesity |
CAMC Health System |
2016-08-01 | |
| NCT03795233 | TERMINATED | Clostridium Difficile Infection |
Boston Medical Center |
2019-08-23 | PHASE1; PHASE2 |
| NCT03795233 | TERMINATED | Clostridium Difficile Infection |
Boston Medical Center |
2019-08-23 | PHASE1; PHASE2 |
| NCT03688659 | UNKNOWN | Infective Endocarditis |
Assiut University |
2019-01-01 | |
| NCT03688659 | UNKNOWN | Infective Endocarditis |
Assiut University |
2019-01-01 | |
| NCT03476317 | COMPLETED | Crohn Disease |
Children's Hospital of Philadelphia |
2018-07-12 | PHASE2 |
| NCT03476317 | COMPLETED | Crohn Disease |
Children's Hospital of Philadelphia |
2018-07-12 | PHASE2 |
| NCT04044703 | COMPLETED | Sepsis; Infection; Bacteremia |
Murdoch Childrens Research Institute |
2019-08-30 | PHASE4 |
| NCT04044703 | COMPLETED | Sepsis; Infection; Bacteremia |
Murdoch Childrens Research Institute |
2019-08-30 | PHASE4 |
| NCT03432858 | COMPLETED | Carpal Tunnel Syndrome |
WellSpan Health |
2018-05-17 | PHASE4 |
| NCT03432858 | COMPLETED | Carpal Tunnel Syndrome |
WellSpan Health |
2018-05-17 | PHASE4 |
| NCT04042077 | TERMINATED | Surgical Site Infection |
Menarini Group |
2019-09-25 | PHASE3 |
| NCT04042077 | TERMINATED | Surgical Site Infection |
Menarini Group |
2019-09-25 | PHASE3 |
| NCT03822819 | UNKNOWN | Vancomycin-Resistant Enterococci; Probiotics |
Taipei Medical University Shuang Ho Hospital |
2019-03-15 | |
| NCT03822819 | UNKNOWN | Vancomycin-Resistant Enterococci; Probiotics |
Taipei Medical University Shuang Ho Hospital |
2019-03-15 | |
| NCT03964493 | COMPLETED | Skin and Subcutaneous Tissue Bacterial Infections; Gram-Positive Bacterial Infections |
TenNor Therapeutics Limited |
2019-04-20 | PHASE2 |
| NCT03964493 | COMPLETED | Skin and Subcutaneous Tissue Bacterial Infections; Gram-Positive Bacterial Infections |
TenNor Therapeutics Limited |
2019-04-20 | PHASE2 |
| NCT03685747 | COMPLETED | Peritoneal Dialysis-associated Peritonitis |
Thomas Jefferson University |
2018-11-15 | PHASE1 |
| NCT03685747 | COMPLETED | Peritoneal Dialysis-associated Peritonitis |
Thomas Jefferson University |
2018-11-15 | PHASE1 |
| NCT03721328 | COMPLETED | Prosthetic Joint Infection |
Osteal Therapeutics, Inc. |
2018-10-26 | PHASE2 |
| NCT03721328 | COMPLETED | Prosthetic Joint Infection |
Osteal Therapeutics, Inc. |
2018-10-26 | PHASE2 |
| NCT04297631 | COMPLETED | Antibotics in Cementless Knees |
Washington University School of Medicine |
2020-02-14 | PHASE4 |
| NCT04297631 | COMPLETED | Antibotics in Cementless Knees |
Washington University School of Medicine |
2020-02-14 | PHASE4 |
| NCT03181932 | COMPLETED | MRSA; Cystic Fibrosis |
Savara Inc. |
2017-09-20 | PHASE3 |
| NCT03181932 | COMPLETED | MRSA; Cystic Fibrosis |
Savara Inc. |
2017-09-20 | PHASE3 |
| NCT03921099 | UNKNOWN | Acute Kidney Injury |
Ain Shams University |
2019-01-17 | PHASE4 |
| NCT03921099 | UNKNOWN | Acute Kidney Injury |
Ain Shams University |
2019-01-17 | PHASE4 |
| NCT03030248 | COMPLETED | Clostridium Difficile Infection; Hematologic Diseases; Bone Marrow Transplant; Oncologic Disorders |
Medical College of Wisconsin |
2018-06-01 | PHASE2 |
| NCT03030248 | COMPLETED | Clostridium Difficile Infection; Hematologic Diseases; Bone Marrow Transplant; Oncologic Disorders |
Medical College of Wisconsin |
2018-06-01 | PHASE2 |
| NCT02790996 | TERMINATED | Late Onset Neonatal Sepsis |
PENTA Foundation |
2017-02-27 | PHASE2 |
| NCT02790996 | TERMINATED | Late Onset Neonatal Sepsis |
PENTA Foundation |
2017-02-27 | PHASE2 |
| NCT01792804 | COMPLETED | Staphylococcus Aureus Infection |
Heinrich-Heine University, Duesseldorf |
2013-12 | PHASE3 |
| NCT01792804 | COMPLETED | Staphylococcus Aureus Infection |
Heinrich-Heine University, Duesseldorf |
2013-12 | PHASE3 |
| NCT02865616 | COMPLETED | Clostridium Difficile Infection |
NuBiyota |
2017-10-27 | PHASE1 |
| NCT02865616 | COMPLETED | Clostridium Difficile Infection |
NuBiyota |
2017-10-27 | PHASE1 |
| NCT03439124 | COMPLETED | Community-acquired Pneumonia (CAP); Hospital-acquired Pneumonia (HAP) |
Basilea Pharmaceutica |
2017-11-27 | PHASE3 |
| NCT03439124 | COMPLETED | Community-acquired Pneumonia (CAP); Hospital-acquired Pneumonia (HAP) |
Basilea Pharmaceutica |
2017-11-27 | PHASE3 |
| NCT03438214 | UNKNOWN | Gram-Positive Bacterial Infections; Nephrotoxicity; Sepsis |
University of Sao Paulo |
2018-04-28 | PHASE4 |
| NCT03438214 | UNKNOWN | Gram-Positive Bacterial Infections; Nephrotoxicity; Sepsis |
University of Sao Paulo |
2018-04-28 | PHASE4 |
| NCT04241744 | WITHDRAWN | CDI |
Creighton University |
2019-10-29 | PHASE4 |
| NCT04241744 | WITHDRAWN | CDI |
Creighton University |
2019-10-29 | PHASE4 |
| NCT02284126 | COMPLETED | Infection; Surgery; Nervous System Diseases |
Columbia University |
2014-10 | PHASE3 |
| NCT02284126 | COMPLETED | Infection; Surgery; Nervous System Diseases |
Columbia University |
2014-10 | PHASE3 |
| NCT03928522 | COMPLETED | Total Knee Replacement |
Washington University School of Medicine |
2019-01-28 | PHASE4 |
| NCT03928522 | COMPLETED | Total Knee Replacement |
Washington University School of Medicine |
2019-01-28 | PHASE4 |
| NCT02466698 | UNKNOWN | Clostridium Difficile |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2016-08 | PHASE2; PHASE3 |
| NCT02466698 | UNKNOWN | Clostridium Difficile |
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
2016-08 | PHASE2; PHASE3 |
| NCT03308253 | UNKNOWN | Surgical Site Infection |
McMaster University |
2018-07-16 | PHASE4 |
| NCT03308253 | UNKNOWN | Surgical Site Infection |
McMaster University |
2018-07-16 | PHASE4 |
| NCT03137173 | COMPLETED | Acute Bacterial Skin and Skin Structure Infections |
Basilea Pharmaceutica |
2018-02-19 | PHASE3 |
| NCT03137173 | COMPLETED | Acute Bacterial Skin and Skin Structure Infections |
Basilea Pharmaceutica |
2018-02-19 | PHASE3 |
| NCT02374853 | TERMINATED | INFECTION |
University of Alberta |
2015-03 | PHASE2 |
| NCT02374853 | TERMINATED | INFECTION |
University of Alberta |
2015-03 | PHASE2 |
| NCT02037295 | COMPLETED | Obesity |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2014-01-14 | PHASE2 |
| NCT02037295 | COMPLETED | Obesity |
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
2014-01-14 | PHASE2 |
| NCT04236778 | COMPLETED | Healthy Volunteers |
Vedanta Biosciences, Inc. |
2017-11-28 | PHASE1 |
| NCT04236778 | COMPLETED | Healthy Volunteers |
Vedanta Biosciences, Inc. |
2017-11-28 | PHASE1 |
| NCT02631408 | COMPLETED | Spinal Fusion Acquired |
Orthopedic Hospital Vienna Speising |
2015-08 | PHASE4 |
| NCT02631408 | COMPLETED | Spinal Fusion Acquired |
Orthopedic Hospital Vienna Speising |
2015-08 | PHASE4 |
| NCT03046901 | WITHDRAWN | Primary Sclerosing Cholangitis; Post- Orthotopic Liver Transplantation |
Ochsner Health System |
2016-12-07 | |
| NCT03046901 | WITHDRAWN | Primary Sclerosing Cholangitis; Post- Orthotopic Liver Transplantation |
Ochsner Health System |
2016-12-07 | |
| NCT02743234 | COMPLETED | Clostridium Difficile Infection |
University of Aarhus |
2016-04 | PHASE3 |
| NCT02743234 | COMPLETED | Clostridium Difficile Infection |
University of Aarhus |
2016-04 | PHASE3 |
| NCT03506347 | COMPLETED | Arthropathy of Knee Joint |
Mayo Clinic |
2018-09-24 | PHASE2; PHASE3 |
| NCT03506347 | COMPLETED | Arthropathy of Knee Joint |
Mayo Clinic |
2018-09-24 | PHASE2; PHASE3 |
| NCT03585426 | UNKNOWN | Vancomycin |
Xijing Hospital |
2016-03 | PHASE4 |
| NCT03585426 | UNKNOWN | Vancomycin |
Xijing Hospital |
2016-03 | PHASE4 |
| NCT02765256 | COMPLETED | Crohn's Disease |
University of Pennsylvania |
2016-08 | PHASE2 |
| NCT02765256 | COMPLETED | Crohn's Disease |
University of Pennsylvania |
2016-08 | PHASE2 |
| NCT02774382 | UNKNOWN | Clostridium Difficile |
Hvidovre University Hospital |
2017-05-01 | PHASE3 |
| NCT02774382 | UNKNOWN | Clostridium Difficile |
Hvidovre University Hospital |
2017-05-01 | PHASE3 |
| NCT02400112 | TERMINATED | Fractures, Open; Surgical Wound Infection |
University of Tennessee |
2015-03 | PHASE4 |
| NCT02400112 | TERMINATED | Fractures, Open; Surgical Wound Infection |
University of Tennessee |
2015-03 | PHASE4 |
| NCT02857582 | COMPLETED | Clostridium Difficile |
Per Hellström |
2014-10 | PHASE2 |
| NCT02857582 | COMPLETED | Clostridium Difficile |
Per Hellström |
2014-10 | PHASE2 |
| NCT02344511 | WITHDRAWN | Osteomyelitis |
Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) |
2016-03 | PHASE3 |
| NCT02344511 | WITHDRAWN | Osteomyelitis |
Durata Therapeutics International BV (an Affiliate of Actavis, Inc.) |
2016-03 | PHASE3 |
| NCT03063437 | COMPLETED | Antibiotic Resistant Strain |
Microbiome Health Research Institute |
2017-08-17 | PHASE2 |
| NCT03063437 | COMPLETED | Antibiotic Resistant Strain |
Microbiome Health Research Institute |
2017-08-17 | PHASE2 |
| NCT03412500 | UNKNOWN | Methicillin-Resistant Staphylococcus Aureus |
Pinyo Rattanaumpawan |
2016-10 | PHASE4 |
| NCT03412500 | UNKNOWN | Methicillin-Resistant Staphylococcus Aureus |
Pinyo Rattanaumpawan |
2016-10 | PHASE4 |
| NCT03452189 | COMPLETED | End Stage Renal Disease |
NYU Langone Health |
2017-11-27 | PHASE2 |
| NCT03452189 | COMPLETED | End Stage Renal Disease |
NYU Langone Health |
2017-11-27 | PHASE2 |
| NCT03157388 | COMPLETED | Alcoholic Hepatitis |
University of Aarhus |
2017-06-01 | |
| NCT03157388 | COMPLETED | Alcoholic Hepatitis |
University of Aarhus |
2017-06-01 | |
| NCT02227446 | COMPLETED | Post Operative Surgical Site Infection |
Major Extremity Trauma Research Consortium |
2014-10 | PHASE3 |
| NCT02227446 | COMPLETED | Post Operative Surgical Site Infection |
Major Extremity Trauma Research Consortium |
2014-10 | PHASE3 |
| NCT02432807 | COMPLETED | Bacterial Conjunctivitis |
Kurobe LLC |
2015-05 | PHASE3 |
| NCT02432807 | COMPLETED | Bacterial Conjunctivitis |
Kurobe LLC |
2015-05 | PHASE3 |
| NCT02137668 | RECRUITING | Primary Sclerosing Cholangitis; Biliary Atresia |
Sacramento Pediatric Gastroenterology |
2010-07 | PHASE1 |
| NCT02137668 | RECRUITING | Primary Sclerosing Cholangitis; Biliary Atresia |
Sacramento Pediatric Gastroenterology |
2010-07 | PHASE1 |
| NCT03105479 | TERMINATED | Clostridium Difficile Infection |
Actelion |
2017-04-14 | PHASE2; PHASE3 |
| NCT03105479 | TERMINATED | Clostridium Difficile Infection |
Actelion |
2017-04-14 | PHASE2; PHASE3 |
| NCT02208063 | TERMINATED | Bacteremia |
Cumberland Pharmaceuticals |
2014-12 | PHASE3 |
| NCT02208063 | TERMINATED | Bacteremia |
Cumberland Pharmaceuticals |
2014-12 | PHASE3 |
| NCT02210169 | COMPLETED | Sepsis; Infection; Bacteremia |
Murdoch Childrens Research Institute |
2014-09 | |
| NCT02210169 | COMPLETED | Sepsis; Infection; Bacteremia |
Murdoch Childrens Research Institute |
2014-09 | |
| NCT02218372 | COMPLETED | Clostridium Difficile-associated Diarrhea (CDAD) |
Astellas Pharma Europe B.V. |
2015-01-09 | PHASE3 |
| NCT02218372 | COMPLETED | Clostridium Difficile-associated Diarrhea (CDAD) |
Astellas Pharma Europe B.V. |
2015-01-09 | PHASE3 |
| NCT03403972 | COMPLETED | Simvastatin Pharmacokinetics and Gut Microbiome |
Seoul National University Hospital |
2017-12-06 | PHASE1 |
| NCT03403972 | COMPLETED | Simvastatin Pharmacokinetics and Gut Microbiome |
Seoul National University Hospital |
2017-12-06 | PHASE1 |
| NCT02730962 | TERMINATED | Pre-Diabetes |
University of Minnesota |
2016-06 | PHASE2 |
| NCT02730962 | TERMINATED | Pre-Diabetes |
University of Minnesota |
2016-06 | PHASE2 |
| NCT02570477 | UNKNOWN | Clostridium Difficile Infection |
Chinese University of Hong Kong |
2015-01 | |
| NCT02570477 | UNKNOWN | Clostridium Difficile Infection |
Chinese University of Hong Kong |
2015-01 | |
| NCT01594827 | COMPLETED | Cystic Fibrosis |
Johns Hopkins University |
2012-10 | PHASE2 |
| NCT01594827 | COMPLETED | Cystic Fibrosis |
Johns Hopkins University |
2012-10 | PHASE2 |
| NCT03273296 | COMPLETED | Microbial Colonization |
Finnish Institute for Health and Welfare |
2017-10-15 | PHASE4 |
| NCT03273296 | COMPLETED | Microbial Colonization |
Finnish Institute for Health and Welfare |
2017-10-15 | PHASE4 |
| NCT02618187 | COMPLETED | Ulcerative Colitis |
Seres Therapeutics, Inc. |
2016-01-13 | PHASE1 |
| NCT02618187 | COMPLETED | Ulcerative Colitis |
Seres Therapeutics, Inc. |
2016-01-13 | PHASE1 |
| NCT01925066 | COMPLETED | Pneumonia, Staphylococcal; Methicillin-Resistant Staphylococcus Aureus |
Seoul National University Hospital |
2013-08 | PHASE2 |
| NCT01925066 | COMPLETED | Pneumonia, Staphylococcal; Methicillin-Resistant Staphylococcus Aureus |
Seoul National University Hospital |
2013-08 | PHASE2 |
| NCT03053505 | UNKNOWN | Clostridium Difficile Infection |
Sejtterapia Kozpont Kft. |
2017-01 | |
| NCT03053505 | UNKNOWN | Clostridium Difficile Infection |
Sejtterapia Kozpont Kft. |
2017-01 | |
| NCT02926846 | COMPLETED | Peritonitis; Kidney Failure |
Alice Ho Miu Ling Nethersole Hospital |
2014-03 | PHASE4 |
| NCT02926846 | COMPLETED | Peritonitis; Kidney Failure |
Alice Ho Miu Ling Nethersole Hospital |
2014-03 | PHASE4 |
| NCT03427229 | COMPLETED | Clostridium Difficile; Pseudomembranous Colitis |
Catholic University of the Sacred Heart |
2016-03 | PHASE2 |
| NCT03427229 | COMPLETED | Clostridium Difficile; Pseudomembranous Colitis |
Catholic University of the Sacred Heart |
2016-03 | PHASE2 |
| NCT02241005 | COMPLETED | Hematopoietic Stem Cell Transplantation; Vancomycin-Resistant Enterococci |
St. Jude Children's Research Hospital |
2014-10-30 | |
| NCT02241005 | COMPLETED | Hematopoietic Stem Cell Transplantation; Vancomycin-Resistant Enterococci |
St. Jude Children's Research Hospital |
2014-10-30 | |
| NCT02660346 | COMPLETED | Bacteremia |
Sharp HealthCare |
2015-11 | PHASE4 |
| NCT02660346 | COMPLETED | Bacteremia |
Sharp HealthCare |
2015-11 | PHASE4 |
| NCT02607618 | COMPLETED | Skin Structures and Soft Tissue Infections |
Motif Bio |
2015-11 | PHASE3 |
| NCT02607618 | COMPLETED | Skin Structures and Soft Tissue Infections |
Motif Bio |
2015-11 | PHASE3 |
| NCT02057198 | COMPLETED | C. Difficile; Diarrhea; Enterocolitis |
Duke University |
2014-06-10 | PHASE4 |
| NCT02057198 | COMPLETED | C. Difficile; Diarrhea; Enterocolitis |
Duke University |
2014-06-10 | PHASE4 |
| NCT01828892 | UNKNOWN | Low-output External Gastrointestinal Fistula |
Jinling Hospital, China |
2014-03 | |
| NCT01828892 | UNKNOWN | Low-output External Gastrointestinal Fistula |
Jinling Hospital, China |
2014-03 | |
| NCT02463747 | UNKNOWN | Fever; Febrile Neutropenia |
Tel-Aviv Sourasky Medical Center |
2015-06 | PHASE4 |
| NCT02463747 | UNKNOWN | Fever; Febrile Neutropenia |
Tel-Aviv Sourasky Medical Center |
2015-06 | PHASE4 |
| NCT02154061 | COMPLETED | Influenza |
Emory University |
2015-04 | |
| NCT02154061 | COMPLETED | Influenza |
Emory University |
2015-04 | |
| NCT02464020 | COMPLETED | Primary Sclerosing Cholangitis; Inflammatory Bowel Disease |
University of Minnesota |
2015-07 | PHASE1 |
| NCT02464020 | COMPLETED | Primary Sclerosing Cholangitis; Inflammatory Bowel Disease |
University of Minnesota |
2015-07 | PHASE1 |
| NCT02951702 | COMPLETED | Clostridium Difficile Infection; Prophylaxis; Vancomycin |
St. Luke's Hospital, Chesterfield, Missouri |
2016-11 | PHASE4 |
| NCT02951702 | COMPLETED | Clostridium Difficile Infection; Prophylaxis; Vancomycin |
St. Luke's Hospital, Chesterfield, Missouri |
2016-11 | PHASE4 |
| NCT01983683 | COMPLETED | Clostridium Difficile Infection |
Actelion |
2013-12-12 | PHASE3 |
| NCT01983683 | COMPLETED | Clostridium Difficile Infection |
Actelion |
2013-12-12 | PHASE3 |
| NCT01191840 | COMPLETED | Bacteremia |
Duke University |
2011-02 | PHASE2 |
| NCT01191840 | COMPLETED | Bacteremia |
Duke University |
2011-02 | PHASE2 |
| NCT02694458 | COMPLETED | Methicillin-resistant Staphylococcal Infections |
Assistance Publique - Hôpitaux de Paris |
2016-02-23 | |
| NCT02694458 | COMPLETED | Methicillin-resistant Staphylococcal Infections |
Assistance Publique - Hôpitaux de Paris |
2016-02-23 | |
| NCT02384200 | COMPLETED | Nephrolithiasis; Urinary Tract Infections |
University of California, San Diego |
2015-03 | PHASE4 |
| NCT02384200 | COMPLETED | Nephrolithiasis; Urinary Tract Infections |
University of California, San Diego |
2015-03 | PHASE4 |
| NCT02478710 | TERMINATED | Pneumonia, Ventilator-Associated |
Wright State University |
2015-06 | PHASE4 |
| NCT02478710 | TERMINATED | Pneumonia, Ventilator-Associated |
Wright State University |
2015-06 | PHASE4 |
| NCT02600611 | COMPLETED | Skin Structures and Soft Tissue Infections |
Motif Bio |
2015-11-01 | PHASE3 |
| NCT02600611 | COMPLETED | Skin Structures and Soft Tissue Infections |
Motif Bio |
2015-11-01 | PHASE3 |
| NCT02411331 | UNKNOWN | Lock Solution; Catheter Related Blood Stream Infections; Central Venous Catheter Infection; Intravenous Drug Delivery Systems; Coagulase-negative Staphylococci Infection |
University Hospital, Clermont-Ferrand |
2015-03 | |
| NCT02411331 | UNKNOWN | Lock Solution; Catheter Related Blood Stream Infections; Central Venous Catheter Infection; Intravenous Drug Delivery Systems; Coagulase-negative Staphylococci Infection |
University Hospital, Clermont-Ferrand |
2015-03 | |
| NCT02307006 | UNKNOWN | Surgical Site Infection |
University of Cincinnati |
2015-01 | PHASE4 |
| NCT02307006 | UNKNOWN | Surgical Site Infection |
University of Cincinnati |
2015-01 | PHASE4 |
| NCT02355938 | TERMINATED | Clostridium Difficile; Spinal Cord Injury |
Baylor College of Medicine |
2014-02 | PHASE4 |
| NCT02355938 | TERMINATED | Clostridium Difficile; Spinal Cord Injury |
Baylor College of Medicine |
2014-02 | PHASE4 |
| NCT02179658 | COMPLETED | Clostridium Difficile |
Astellas Pharma Inc |
2014-06-23 | PHASE3 |
| NCT02179658 | COMPLETED | Clostridium Difficile |
Astellas Pharma Inc |
2014-06-23 | PHASE3 |
| NCT02426918 | COMPLETED | Bacterial Infections |
Debiopharm International SA |
2015-05 | PHASE2 |
| NCT02426918 | COMPLETED | Bacterial Infections |
Debiopharm International SA |
2015-05 | PHASE2 |
| NCT02237859 | UNKNOWN | Clostridium Difficile Infection |
Corewell Health West |
2014-08 | PHASE4 |
| NCT02237859 | UNKNOWN | Clostridium Difficile Infection |
Corewell Health West |
2014-08 | PHASE4 |
| NCT02732327 | TERMINATED | Neoplasms; Febrile Neutropenia |
Forest Laboratories |
2016-05-17 | PHASE2 |
| NCT02732327 | TERMINATED | Neoplasms; Febrile Neutropenia |
Forest Laboratories |
2016-05-17 | PHASE2 |
| NCT01922011 | COMPLETED | Acute Hematogenous Osteomyelitis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2013-09-13 | PHASE3 |
| NCT01922011 | COMPLETED | Acute Hematogenous Osteomyelitis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2013-09-13 | PHASE3 |
| NCT01786161 | TERMINATED | MRSA - Methicillin Resistant Staphylococcus Aureus Infection |
Massachusetts General Hospital |
2013-09 | PHASE4 |
| NCT01786161 | TERMINATED | MRSA - Methicillin Resistant Staphylococcus Aureus Infection |
Massachusetts General Hospital |
2013-09 | PHASE4 |
| NCT02582203 | COMPLETED | Skin Diseases, Infectious; Staphylococcal Skin Infections |
Wayne State University |
2012-02 | PHASE4 |
| NCT02582203 | COMPLETED | Skin Diseases, Infectious; Staphylococcal Skin Infections |
Wayne State University |
2012-02 | PHASE4 |
| NCT02787057 | COMPLETED | Peritoneal Dialysis Associated Peritonitis |
Peking University First Hospital |
2012-11 | |
| NCT02787057 | COMPLETED | Peritoneal Dialysis Associated Peritonitis |
Peking University First Hospital |
2012-11 | |
| NCT02504554 | COMPLETED | Gastrointestinal Problems; Autism Spectrum Disorders |
Arizona State University |
2014-07 | PHASE1; PHASE2 |
| NCT02504554 | COMPLETED | Gastrointestinal Problems; Autism Spectrum Disorders |
Arizona State University |
2014-07 | PHASE1; PHASE2 |
| NCT01757236 | UNKNOWN | Hip Prosthetic Joint Infection |
University Hospital, Tours |
2012-10 | PHASE2 |
| NCT01757236 | UNKNOWN | Hip Prosthetic Joint Infection |
University Hospital, Tours |
2012-10 | PHASE2 |
| NCT02254967 | COMPLETED | Clostridium Difficile |
Astellas Pharma Europe Ltd. |
2014-11-06 | PHASE4 |
| NCT02254967 | COMPLETED | Clostridium Difficile |
Astellas Pharma Europe Ltd. |
2014-11-06 | PHASE4 |
| NCT02301221 | UNKNOWN | Slow Transit Constipation |
Jinling Hospital, China |
2015-03 | PHASE2 |
| NCT02301221 | UNKNOWN | Slow Transit Constipation |
Jinling Hospital, China |
2015-03 | PHASE2 |
| NCT02443064 | UNKNOWN | Blood Stream Infections; Endocarditis; MRSA |
Zhejiang University |
2014-01 | PHASE4 |
| NCT02443064 | UNKNOWN | Blood Stream Infections; Endocarditis; MRSA |
Zhejiang University |
2014-01 | PHASE4 |
| NCT02127749 | COMPLETED | Endotoxemia |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-06 | |
| NCT02127749 | COMPLETED | Endotoxemia |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-06 | |
| NCT01975662 | TERMINATED | Bacteremia Due to Staphylococcus Aureus |
Singapore General Hospital |
2014-01 | PHASE2 |
| NCT01975662 | TERMINATED | Bacteremia Due to Staphylococcus Aureus |
Singapore General Hospital |
2014-01 | PHASE2 |
| NCT03720132 | TERMINATED | Catheter Related Blood Stream Infections |
Universitaire Ziekenhuizen KU Leuven |
2014-06 | |
| NCT03720132 | TERMINATED | Catheter Related Blood Stream Infections |
Universitaire Ziekenhuizen KU Leuven |
2014-06 | |
| NCT01977989 | UNKNOWN | Wound Infection |
University of Tennessee |
2013-10 | PHASE4 |
| NCT01977989 | UNKNOWN | Wound Infection |
University of Tennessee |
2013-10 | PHASE4 |
| NCT02092935 | COMPLETED | Clostridium Difficile Infection |
Summit Therapeutics |
2014-04 | PHASE2 |
| NCT02092935 | COMPLETED | Clostridium Difficile Infection |
Summit Therapeutics |
2014-04 | PHASE2 |
| NCT03107169 | COMPLETED | Clostridium Difficile Infection |
Universidad Autonoma de Nuevo Leon |
2015-02-01 | |
| NCT03107169 | COMPLETED | Clostridium Difficile Infection |
Universidad Autonoma de Nuevo Leon |
2015-02-01 | |
| NCT01720940 | UNKNOWN | Infections Requiring Prolonged Duration (>10 Days) of Vancomycin |
National University Hospital, Singapore |
2012-10 | |
| NCT01720940 | UNKNOWN | Infections Requiring Prolonged Duration (>10 Days) of Vancomycin |
National University Hospital, Singapore |
2012-10 | |
| NCT02299882 | UNKNOWN | Lumbar Pain |
Corewell Health West |
2012-08 | |
| NCT02299882 | UNKNOWN | Lumbar Pain |
Corewell Health West |
2012-08 | |
| NCT01802073 | COMPLETED | Primary Sclerosing Cholangitis |
Stanford University |
2012-01 | PHASE3 |
| NCT01802073 | COMPLETED | Primary Sclerosing Cholangitis |
Stanford University |
2012-01 | PHASE3 |
| NCT01598311 | COMPLETED | Clostridium Difficile Infection |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2012-05-16 | PHASE3 |
| NCT01598311 | COMPLETED | Clostridium Difficile Infection |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2012-05-16 | PHASE3 |
| NCT01798537 | UNKNOWN | Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia |
Rambam Health Care Campus |
2013-06 | PHASE2; PHASE3 |
| NCT01798537 | UNKNOWN | Bacteremia Associated With Intravascular Line; Ventilator Associated Pneumonia; Bacteremia |
Rambam Health Care Campus |
2013-06 | PHASE2; PHASE3 |
| NCT02020031 | COMPLETED | Arthropathy of Knee Joint |
Mayo Clinic |
2013-12 | PHASE2; PHASE3 |
| NCT02020031 | COMPLETED | Arthropathy of Knee Joint |
Mayo Clinic |
2013-12 | PHASE2; PHASE3 |
| NCT02027532 | TERMINATED | Infection; Closed Fractures |
University of Tennessee |
2009-10 | |
| NCT02027532 | TERMINATED | Infection; Closed Fractures |
University of Tennessee |
2009-10 | |
| NCT02945241 | COMPLETED | Methicillin-resistant Staphylococcus Aureus; Sepsis; Critical Illness |
Mayo Clinic |
2014-04 | PHASE1 |
| NCT02945241 | COMPLETED | Methicillin-resistant Staphylococcus Aureus; Sepsis; Critical Illness |
Mayo Clinic |
2014-04 | PHASE1 |
| NCT02051595 | COMPLETED | Infection |
University of Florida |
2014-04 | EARLY_PHASE1 |
| NCT02051595 | COMPLETED | Infection |
University of Florida |
2014-04 | EARLY_PHASE1 |
| NCT01570192 | TERMINATED | Bacterial Pneumonia |
University of Florida |
2010-09 | PHASE2 |
| NCT01570192 | TERMINATED | Bacterial Pneumonia |
University of Florida |
2010-09 | PHASE2 |
| NCT01597505 | COMPLETED | Clostridium Difficile Infection |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2012-05-16 | PHASE3 |
| NCT01597505 | COMPLETED | Clostridium Difficile Infection |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2012-05-16 | PHASE3 |
| NCT01952834 | COMPLETED | Coronary Artery Disease |
Medical College of Wisconsin |
2013-06 | PHASE4 |
| NCT01952834 | COMPLETED | Coronary Artery Disease |
Medical College of Wisconsin |
2013-06 | PHASE4 |
| NCT01626560 | COMPLETED | Cellulitis |
Hospital Universitario Evangelico de Curitiba |
2012-07 | PHASE4 |
| NCT01626560 | COMPLETED | Cellulitis |
Hospital Universitario Evangelico de Curitiba |
2012-07 | PHASE4 |
| NCT01592032 | UNKNOWN | Catheter-Related Infections; Bacteremia. |
Clinica Universidad de Navarra, Universidad de Navarra |
2012-05 | PHASE4 |
| NCT01592032 | UNKNOWN | Catheter-Related Infections; Bacteremia. |
Clinica Universidad de Navarra, Universidad de Navarra |
2012-05 | PHASE4 |
| NCT00915967 | COMPLETED | Surgical Wound Infections |
Oregon Health and Science University |
2009-05-13 | |
| NCT00915967 | COMPLETED | Surgical Wound Infections |
Oregon Health and Science University |
2009-05-13 | |
| NCT01818141 | COMPLETED | Clostridium Difficile Infection |
Hartford Hospital |
2012-10-17 | PHASE4 |
| NCT01818141 | COMPLETED | Clostridium Difficile Infection |
Hartford Hospital |
2012-10-17 | PHASE4 |
| NCT01619982 | COMPLETED | Congenital Heart Diseases; Aortic Valve Disorder |
Stanford University |
2012-02 | PHASE4 |
| NCT01619982 | COMPLETED | Congenital Heart Diseases; Aortic Valve Disorder |
Stanford University |
2012-02 | PHASE4 |
| NCT01566422 | WITHDRAWN | Surgical Site Infection |
Vanderbilt University Medical Center |
2012-06 | |
| NCT01566422 | WITHDRAWN | Surgical Site Infection |
Vanderbilt University Medical Center |
2012-06 | |
| NCT01942447 | UNKNOWN | Clostridium Difficile; Clostridium Difficile Infection |
University Hospital Tuebingen |
2013-10 | |
| NCT01942447 | UNKNOWN | Clostridium Difficile; Clostridium Difficile Infection |
University Hospital Tuebingen |
2013-10 | |
| NCT01746095 | COMPLETED | Cystic Fibrosis |
Savara Inc. |
2013-03 | PHASE2 |
| NCT01746095 | COMPLETED | Cystic Fibrosis |
Savara Inc. |
2013-03 | PHASE2 |
| NCT02148601 | COMPLETED | Clostridium Difficile |
Catholic University of the Sacred Heart |
2013-07 | PHASE2 |
| NCT02148601 | COMPLETED | Clostridium Difficile |
Catholic University of the Sacred Heart |
2013-07 | PHASE2 |
| NCT01226992 | TERMINATED | Recurrent Clostridium Difficile Infection; Laboratory Confirmed Clostridium Difficile Infection |
University Health Network, Toronto |
2010-10 | PHASE2; PHASE3 |
| NCT01226992 | TERMINATED | Recurrent Clostridium Difficile Infection; Laboratory Confirmed Clostridium Difficile Infection |
University Health Network, Toronto |
2010-10 | PHASE2; PHASE3 |
| NCT02241421 | COMPLETED | Obesity; Insulin Resistance |
Maastricht University Medical Center |
2012-04 | |
| NCT02241421 | COMPLETED | Obesity; Insulin Resistance |
Maastricht University Medical Center |
2012-04 | |
| NCT01811732 | COMPLETED | Skin and Subcutaneous Tissue Bacterial Infections |
Melinta Therapeutics, Inc. |
2013-04 | PHASE3 |
| NCT01811732 | COMPLETED | Skin and Subcutaneous Tissue Bacterial Infections |
Melinta Therapeutics, Inc. |
2013-04 | PHASE3 |
| NCT00871104 | COMPLETED | Infective Endocarditis |
Juan A. Arnaiz |
2009-07 | PHASE4 |
| NCT00871104 | COMPLETED | Infective Endocarditis |
Juan A. Arnaiz |
2009-07 | PHASE4 |
| NCT01860469 | UNKNOWN | Patients Undergoing Open Hernia Repair; Patients Undergoing Ventral or Inguinal Hernia Repair |
University of Saskatchewan |
2013-06 | PHASE2; PHASE3 |
| NCT01860469 | UNKNOWN | Patients Undergoing Open Hernia Repair; Patients Undergoing Ventral or Inguinal Hernia Repair |
University of Saskatchewan |
2013-06 | PHASE2; PHASE3 |
| NCT01499277 | COMPLETED | Complicated Skin and Soft Tissue Infection |
Pfizer |
2012-05 | PHASE3 |
| NCT01499277 | COMPLETED | Complicated Skin and Soft Tissue Infection |
Pfizer |
2012-05 | PHASE3 |
| NCT00911573 | WITHDRAWN | Skin Diseases; Infection |
Wyeth is now a wholly owned subsidiary of Pfizer |
2011-08 | PHASE3 |
| NCT01669980 | COMPLETED | Infections; Pneumonia |
Forest Laboratories |
2012-10 | PHASE4 |
| NCT00911573 | WITHDRAWN | Skin Diseases; Infection |
Wyeth is now a wholly owned subsidiary of Pfizer |
2011-08 | PHASE3 |
| NCT01669980 | COMPLETED | Infections; Pneumonia |
Forest Laboratories |
2012-10 | PHASE4 |
| NCT00427076 | COMPLETED | Staphylococcal Infections; Meningitis; Sepsis; Pneumonia |
Rabin Medical Center |
2007-06 | PHASE3 |
| NCT00427076 | COMPLETED | Staphylococcal Infections; Meningitis; Sepsis; Pneumonia |
Rabin Medical Center |
2007-06 | PHASE3 |
| NCT01400867 | COMPLETED | Infections, Pediatrics |
Forest Laboratories |
2011-12 | PHASE2; PHASE3 |
| NCT01400867 | COMPLETED | Infections, Pediatrics |
Forest Laboratories |
2011-12 | PHASE2; PHASE3 |
| NCT01196169 | TERMINATED | Staphylococcal Infections; Methicillin-resistant Staphylococcus Aureus |
Mountain Home Research & Education Corporation |
2010-10 | PHASE4 |
| NCT01196169 | TERMINATED | Staphylococcal Infections; Methicillin-resistant Staphylococcus Aureus |
Mountain Home Research & Education Corporation |
2010-10 | PHASE4 |
| NCT01645735 | COMPLETED | Infections |
Forest Laboratories |
2012-10 | PHASE4 |
| NCT01645735 | COMPLETED | Infections |
Forest Laboratories |
2012-10 | PHASE4 |
| NCT01199783 | TERMINATED | Diabetic Foot |
Ruhr University of Bochum |
2011-07 | PHASE3 |
| NCT01199783 | TERMINATED | Diabetic Foot |
Ruhr University of Bochum |
2011-07 | PHASE3 |
| NCT02340182 | COMPLETED | Healthy; Sepsis |
W.J. Wiersinga, MD, PhD |
2013-03 | |
| NCT02340182 | COMPLETED | Healthy; Sepsis |
W.J. Wiersinga, MD, PhD |
2013-03 | |
| NCT01232595 | COMPLETED | Moderate Clostridium Difficile Infection |
Novartis Pharmaceuticals |
2010-10 | PHASE2 |
| NCT01549613 | COMPLETED | Cellulitis; Skin Infections |
University of Cincinnati |
2012-05 | PHASE4 |
| NCT01549613 | COMPLETED | Cellulitis; Skin Infections |
University of Cincinnati |
2012-05 | PHASE4 |
| NCT01232595 | COMPLETED | Moderate Clostridium Difficile Infection |
Novartis Pharmaceuticals |
2010-10 | PHASE2 |
| NCT01515020 | TERMINATED | Nosocomial Infection; Healthcare-associated Infection |
Assistance Publique - Hôpitaux de Paris |
2012-05 | PHASE3 |
| NCT01515020 | TERMINATED | Nosocomial Infection; Healthcare-associated Infection |
Assistance Publique - Hôpitaux de Paris |
2012-05 | PHASE3 |
| NCT01252732 | COMPLETED | Wound Infection; Abscess; Systemic Inflammation; Cellulitis |
Melinta Therapeutics, Inc. |
2010-12 | PHASE3 |
| NCT01252732 | COMPLETED | Wound Infection; Abscess; Systemic Inflammation; Cellulitis |
Melinta Therapeutics, Inc. |
2010-12 | PHASE3 |
| NCT03453684 | COMPLETED | Surgical Site Infection; Vancomycin |
University of Colorado, Denver |
2012-12-01 | PHASE4 |
| NCT03453684 | COMPLETED | Surgical Site Infection; Vancomycin |
University of Colorado, Denver |
2012-12-01 | PHASE4 |
| NCT01775397 | TERMINATED | Clostridium Difficile |
Astellas Pharma Europe Ltd. |
2012-11-29 | PHASE4 |
| NCT01775397 | TERMINATED | Clostridium Difficile |
Astellas Pharma Europe Ltd. |
2012-11-29 | PHASE4 |
| NCT01633762 | COMPLETED | Diabetes; Obesity; Osteoporosis; Inflammation |
University Hospital, Gentofte, Copenhagen |
2012-04 | EARLY_PHASE1 |
| NCT01633762 | COMPLETED | Diabetes; Obesity; Osteoporosis; Inflammation |
University Hospital, Gentofte, Copenhagen |
2012-04 | EARLY_PHASE1 |
| NCT01612052 | UNKNOWN | MRSA - Methicillin Resistant Staphylococcus Aureus Infection |
CAMC Health System |
2011-05 | PHASE4 |
| NCT01612052 | UNKNOWN | MRSA - Methicillin Resistant Staphylococcus Aureus Infection |
CAMC Health System |
2011-05 | PHASE4 |
| NCT00925093 | WITHDRAWN | Neurosurgery |
Aarhus University Hospital |
2011-09 | PHASE1 |
| NCT01623817 | COMPLETED | Infection |
Samsung Medical Center |
2012-06 | |
| NCT00925093 | WITHDRAWN | Neurosurgery |
Aarhus University Hospital |
2011-09 | PHASE1 |
| NCT01623817 | COMPLETED | Infection |
Samsung Medical Center |
2012-06 | |
| NCT01431339 | COMPLETED | Abscess; Wound Infection; Surgical Site Infection; Cellulitis |
Durata Therapeutics Inc., an affiliate of Allergan plc |
2011-07 | PHASE3 |
| NCT01431339 | COMPLETED | Abscess; Wound Infection; Surgical Site Infection; Cellulitis |
Durata Therapeutics Inc., an affiliate of Allergan plc |
2011-07 | PHASE3 |
| NCT01222702 | COMPLETED | Clostridium Difficile Infection |
Actelion |
2011-01-25 | PHASE2 |
| NCT01222702 | COMPLETED | Clostridium Difficile Infection |
Actelion |
2011-01-25 | PHASE2 |
| NCT01252719 | COMPLETED | Wound Infection; Abscess; Systemic Inflammation; Cellulitis |
Melinta Therapeutics, Inc. |
2010-12 | PHASE3 |
| NCT01252719 | COMPLETED | Wound Infection; Abscess; Systemic Inflammation; Cellulitis |
Melinta Therapeutics, Inc. |
2010-12 | PHASE3 |
| NCT01419184 | COMPLETED | Staphylococcal Skin Infections |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2011-09-09 | PHASE4 |
| NCT01419184 | COMPLETED | Staphylococcal Skin Infections |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2011-09-09 | PHASE4 |
| NCT01734694 | TERMINATED | Health Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia; Acute Bacterial Skin and Skin Structure Infections |
Henry Ford Health System |
2011-10 | PHASE4 |
| NCT01734694 | TERMINATED | Health Care Associated Pneumonia; Osteomyelitis/Septic Arthritis; Endocarditis; Bacteremia; Acute Bacterial Skin and Skin Structure Infections |
Henry Ford Health System |
2011-10 | PHASE4 |
| NCT01339091 | COMPLETED | Abscess; Wound Infection; Surgical Site Infection; Cellulitis |
Durata Therapeutics Inc., an affiliate of Allergan plc |
2011-03 | PHASE3 |
| NCT01339091 | COMPLETED | Abscess; Wound Infection; Surgical Site Infection; Cellulitis |
Durata Therapeutics Inc., an affiliate of Allergan plc |
2011-03 | PHASE3 |
| NCT01133600 | TERMINATED | Diabetic Foot |
Clinical Alliance for Research & Education - Infectious Diseases, LLC. |
2010-08 | PHASE4 |
| NCT01133600 | TERMINATED | Diabetic Foot |
Clinical Alliance for Research & Education - Infectious Diseases, LLC. |
2010-08 | PHASE4 |
| NCT01427842 | UNKNOWN | Vancomycin Therapy |
The Canberra Hospital |
2011-08 | PHASE2 |
| NCT01427842 | UNKNOWN | Vancomycin Therapy |
The Canberra Hospital |
2011-08 | PHASE2 |
| NCT01104662 | TERMINATED | Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2010-04-19 | PHASE4 |
| NCT01104662 | TERMINATED | Complicated Skin and Skin Structure Infections; S. Aureus Bacteremia; Renal Impairment |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2010-04-19 | PHASE4 |
| NCT01372371 | UNKNOWN | Infection |
Ganga Hospital |
2011-06 | |
| NCT01372371 | UNKNOWN | Infection |
Ganga Hospital |
2011-06 | |
| NCT01162733 | COMPLETED | Infectious Disease |
Christiana Care Health Services |
2010-07 | |
| NCT01162733 | COMPLETED | Infectious Disease |
Christiana Care Health Services |
2010-07 | |
| NCT01537666 | COMPLETED | Healthy; Cystic Fibrosis |
Savara Inc. |
2011-11 | PHASE1 |
| NCT01537666 | COMPLETED | Healthy; Cystic Fibrosis |
Savara Inc. |
2011-11 | PHASE1 |
| NCT01346059 | TERMINATED | Colitis |
Corewell Health East |
2011-04 | |
| NCT01346059 | TERMINATED | Colitis |
Corewell Health East |
2011-04 | |
| NCT01290237 | TERMINATED | Infection |
Boston Children's Hospital |
2011-02 | |
| NCT01290237 | TERMINATED | Infection |
Boston Children's Hospital |
2011-02 | |
| NCT01287832 | TERMINATED | Bacteremia |
St. John Health System, Michigan |
2011-06 | PHASE4 |
| NCT01287832 | TERMINATED | Bacteremia |
St. John Health System, Michigan |
2011-06 | PHASE4 |
| NCT01157533 | TERMINATED | Infection |
M.D. Anderson Cancer Center |
2010-06 | |
| NCT01157533 | TERMINATED | Infection |
M.D. Anderson Cancer Center |
2010-06 | |
| NCT01175707 | TERMINATED | Complicated Skin or Skin Structure Infection |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2010-07-15 | PHASE4 |
| NCT01175707 | TERMINATED | Complicated Skin or Skin Structure Infection |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2010-07-15 | PHASE4 |
| NCT01085760 | COMPLETED | Primary Sclerosing Cholangitis |
Mayo Clinic |
2010-02 | PHASE1 |
| NCT01085760 | COMPLETED | Primary Sclerosing Cholangitis |
Mayo Clinic |
2010-02 | PHASE1 |
| NCT01283581 | COMPLETED | Skin and Subcutaneous Tissue Bacterial Infections |
Melinta Therapeutics, Inc. |
2011-01 | PHASE2 |
| NCT01283581 | COMPLETED | Skin and Subcutaneous Tissue Bacterial Infections |
Melinta Therapeutics, Inc. |
2011-01 | PHASE2 |
| NCT01918813 | COMPLETED | Inflammatory Bowel Disease; Hepatobiliary Disease; Pancreas Disease |
Chikara Tashiro |
2009-11 | |
| NCT01918813 | COMPLETED | Inflammatory Bowel Disease; Hepatobiliary Disease; Pancreas Disease |
Chikara Tashiro |
2009-11 | |
| NCT01085591 | COMPLETED | Clostridium Difficile Infection; Diarrhea |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2010-04-01 | PHASE2 |
| NCT01085591 | COMPLETED | Clostridium Difficile Infection; Diarrhea |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2010-04-01 | PHASE2 |
| NCT00818766 | COMPLETED | Antibiotic Prophylaxis |
Brigham and Women's Hospital |
2008-03 | |
| NCT00818766 | COMPLETED | Antibiotic Prophylaxis |
Brigham and Women's Hospital |
2008-03 | |
| NCT01184872 | COMPLETED | Infections |
Novartis Pharmaceuticals |
2010-03 | PHASE3 |
| NCT01184872 | COMPLETED | Infections |
Novartis Pharmaceuticals |
2010-03 | PHASE3 |
| NCT01119105 | COMPLETED | Bacterial Infections; Infection |
Nabriva Therapeutics AG |
2010-05 | PHASE2 |
| NCT01119105 | COMPLETED | Bacterial Infections; Infection |
Nabriva Therapeutics AG |
2010-05 | PHASE2 |
| NCT01322386 | COMPLETED | Primary Sclerosing Cholangitis; Biliary Atresia |
Stanford University |
2007-05 | PHASE1 |
| NCT01322386 | COMPLETED | Primary Sclerosing Cholangitis; Biliary Atresia |
Stanford University |
2007-05 | PHASE1 |
| NCT00933556 | COMPLETED | Anti-biotic Resistance |
University of Wisconsin, Madison |
2008-10 | PHASE2 |
| NCT00933556 | COMPLETED | Anti-biotic Resistance |
University of Wisconsin, Madison |
2008-10 | PHASE2 |
| NCT01037192 | COMPLETED | Skin and Soft Tissue Infections |
Fraser Health |
2010-03 | |
| NCT00772447 | COMPLETED | Skin Diseases; Infectious |
AstraZeneca |
2008-09 | PHASE3 |
| NCT01037192 | COMPLETED | Skin and Soft Tissue Infections |
Fraser Health |
2010-03 | |
| NCT00772447 | COMPLETED | Skin Diseases; Infectious |
AstraZeneca |
2008-09 | PHASE3 |
| NCT00695903 | TERMINATED | Endocarditis, Bacterial; Infective Endocarditis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2008-09-17 | PHASE2 |
| NCT00695903 | TERMINATED | Endocarditis, Bacterial; Infective Endocarditis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2008-09-17 | PHASE2 |
| NCT01867138 | COMPLETED | Nosocomial Neonatal Sepsis |
Hospital Italiano de Buenos Aires |
2007-03 | PHASE3 |
| NCT01867138 | COMPLETED | Nosocomial Neonatal Sepsis |
Hospital Italiano de Buenos Aires |
2007-03 | PHASE3 |
| NCT00428844 | COMPLETED | Osteomyelitis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2007-06-26 | PHASE2 |
| NCT00428844 | COMPLETED | Osteomyelitis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2007-06-26 | PHASE2 |
| NCT00084266 | COMPLETED | Methicillin Resistant Staphylococcus Aureus (MRSA) |
Pfizer |
2004-10 | PHASE4 |
| NCT00084266 | COMPLETED | Methicillin Resistant Staphylococcus Aureus (MRSA) |
Pfizer |
2004-10 | PHASE4 |
| NCT00770341 | COMPLETED | Staphylococcal Infection |
Merck Sharp & Dohme LLC |
2008-09 | PHASE3 |
| NCT00770341 | COMPLETED | Staphylococcal Infection |
Merck Sharp & Dohme LLC |
2008-09 | PHASE3 |
| NCT00591474 | TERMINATED | GI Colonization of Vancomycin-resistant Enterococcus |
Oregon Health and Science University |
2007-12 | |
| NCT00591474 | TERMINATED | GI Colonization of Vancomycin-resistant Enterococcus |
Oregon Health and Science University |
2007-12 | |
| NCT00468728 | COMPLETED | Clostridium Infections; Diarrhea |
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2006-10-04 | PHASE3 |
| NCT00468728 | COMPLETED | Clostridium Infections; Diarrhea |
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2006-10-04 | PHASE3 |
| NCT00861887 | WITHDRAWN | Clostridium Difficile Colitis |
Corewell Health East |
2009-02 | |
| NCT00861887 | WITHDRAWN | Clostridium Difficile Colitis |
Corewell Health East |
2009-02 | |
| NCT00437580 | UNKNOWN | Vancomycin Resistant Enterococcus Intestinal Carriage |
University Hospital, Clermont-Ferrand |
2007-02 | PHASE4 |
| NCT00437580 | UNKNOWN | Vancomycin Resistant Enterococcus Intestinal Carriage |
University Hospital, Clermont-Ferrand |
2007-02 | PHASE4 |
| NCT00543608 | TERMINATED | Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia; Health-Care-Associated Pneumonia |
Arpida AG |
2007-11 | PHASE2 |
| NCT00543608 | TERMINATED | Hospital-Acquired Pneumonia; Ventilator-Associated Pneumonia; Health-Care-Associated Pneumonia |
Arpida AG |
2007-11 | PHASE2 |
| NCT00355602 | COMPLETED | Colitis, Ulcerative |
University of Dundee |
2006-07 | |
| NCT00355602 | COMPLETED | Colitis, Ulcerative |
University of Dundee |
2006-07 | |
| NCT00269399 | COMPLETED | Clostridium Infections; Diarrhea |
Bausch Health Americas, Inc. |
2005-12 | PHASE3 |
| NCT00269399 | COMPLETED | Clostridium Infections; Diarrhea |
Bausch Health Americas, Inc. |
2005-12 | PHASE3 |
| NCT00314951 | COMPLETED | Clostridium Infections; Diarrhea |
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2006-05-02 | PHASE3 |
| NCT00314951 | COMPLETED | Clostridium Infections; Diarrhea |
Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2006-05-02 | PHASE3 |
| NCT00430937 | TERMINATED | Skin Diseases, Infectious; Soft Tissue Infections |
Novartis Pharmaceuticals |
2006-04 | PHASE3 |
| NCT00430937 | TERMINATED | Skin Diseases, Infectious; Soft Tissue Infections |
Novartis Pharmaceuticals |
2006-04 | PHASE3 |
| NCT00529282 | TERMINATED | Fever; Neutropenia; Gram-positive Bacterial Infections; Pseudomonas Infection |
Basilea Pharmaceutica |
2007-10 | PHASE3 |
| NCT00529282 | TERMINATED | Fever; Neutropenia; Gram-positive Bacterial Infections; Pseudomonas Infection |
Basilea Pharmaceutica |
2007-10 | PHASE3 |
| NCT00711685 | COMPLETED | Coronary Artery Disease |
Far Eastern Memorial Hospital |
2007-01 | |
| NCT00423657 | COMPLETED | Bacterial Infections |
Forest Laboratories |
2007-03 | PHASE3 |
| NCT00423657 | COMPLETED | Bacterial Infections |
Forest Laboratories |
2007-03 | PHASE3 |
| NCT00175370 | COMPLETED | Staphylococcal Infections |
University of British Columbia |
2000-09 | |
| NCT00175370 | COMPLETED | Staphylococcal Infections |
University of British Columbia |
2000-09 | |
| NCT00711685 | COMPLETED | Coronary Artery Disease |
Far Eastern Memorial Hospital |
2007-01 | |
| NCT00424190 | COMPLETED | Bacterial Infections |
Forest Laboratories |
2007-02 | PHASE3 |
| NCT00424190 | COMPLETED | Bacterial Infections |
Forest Laboratories |
2007-02 | PHASE3 |
| NCT00384527 | TERMINATED | Clostridium Infections |
Romark Laboratories L.C. |
2006-12 | PHASE3 |
| NCT00384527 | TERMINATED | Clostridium Infections |
Romark Laboratories L.C. |
2006-12 | PHASE3 |
| NCT00426933 | COMPLETED | Soft Tissue Infections |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2007-01 | PHASE2 |
| NCT00426933 | COMPLETED | Soft Tissue Infections |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2007-01 | PHASE2 |
| NCT00454272 | COMPLETED | Infection; Febrile Neutropenia |
Sanofi |
2005-01 | PHASE4 |
| NCT00454272 | COMPLETED | Infection; Febrile Neutropenia |
Sanofi |
2005-01 | PHASE4 |
| NCT00107952 | COMPLETED | Bacterial Pneumonia |
Cumberland Pharmaceuticals |
2005-02 | PHASE3 |
| NCT00107952 | COMPLETED | Bacterial Pneumonia |
Cumberland Pharmaceuticals |
2005-02 | PHASE3 |
| NCT00087490 | COMPLETED | Skin/Soft Tissue Infections; Methicillin Resistant Staphylococcus Aureus (MRSA) |
Pfizer |
2004-10 | PHASE4 |
| NCT00087490 | COMPLETED | Skin/Soft Tissue Infections; Methicillin Resistant Staphylococcus Aureus (MRSA) |
Pfizer |
2004-10 | PHASE4 |
| NCT00324922 | COMPLETED | Osteomyelitis; Methicillin-resistant Staphylococcus Aureus |
University of Washington |
2006-05-01 | PHASE3 |
| NCT00324922 | COMPLETED | Osteomyelitis; Methicillin-resistant Staphylococcus Aureus |
University of Washington |
2006-05-01 | PHASE3 |
| NCT00124020 | COMPLETED | Bacterial Pneumonia |
Cumberland Pharmaceuticals |
2005-01 | PHASE3 |
| NCT00124020 | COMPLETED | Bacterial Pneumonia |
Cumberland Pharmaceuticals |
2005-01 | PHASE3 |
| NCT00442832 | COMPLETED | Staphylococcal Skin Infection |
Theravance Biopharma |
2006-12 | PHASE2 |
| NCT00442832 | COMPLETED | Staphylococcal Skin Infection |
Theravance Biopharma |
2006-12 | PHASE2 |
| NCT00304811 | COMPLETED | Staphylococcus Aureus |
Michael E. DeBakey VA Medical Center |
2006-01 | PHASE4 |
| NCT00304811 | COMPLETED | Staphylococcus Aureus |
Michael E. DeBakey VA Medical Center |
2006-01 | PHASE4 |
| NCT00445094 | COMPLETED | Infection; Pneumonia |
Merck Sharp & Dohme LLC |
2006-11 | PHASE4 |
| NCT00445094 | COMPLETED | Infection; Pneumonia |
Merck Sharp & Dohme LLC |
2006-11 | PHASE4 |
| NCT00210899 | COMPLETED | Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections |
Basilea Pharmaceutica |
2005-09 | PHASE3 |
| NCT00210899 | COMPLETED | Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections |
Basilea Pharmaceutica |
2005-09 | PHASE3 |
| NCT00295178 | COMPLETED | Cellulitis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2006-02-20 | PHASE4 |
| NCT00295178 | COMPLETED | Cellulitis |
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
2006-02-20 | PHASE4 |
| NCT00062647 | COMPLETED | Gram-Positive Bacterial Infections |
Cumberland Pharmaceuticals |
2003-08 | PHASE2 |
| NCT00062647 | COMPLETED | Gram-Positive Bacterial Infections |
Cumberland Pharmaceuticals |
2003-08 | PHASE2 |
| NCT00612469 | COMPLETED | Dental Caries |
Universidade Federal do Ceara |
2005-10 | |
| NCT00612469 | COMPLETED | Dental Caries |
Universidade Federal do Ceara |
2005-10 | |
| NCT00091819 | COMPLETED | Staphylococcal Skin Infection |
Cumberland Pharmaceuticals |
2005-01 | PHASE3 |
| NCT00091819 | COMPLETED | Staphylococcal Skin Infection |
Cumberland Pharmaceuticals |
2005-01 | PHASE3 |
| NCT00251017 | COMPLETED | Adverse Effects |
National Taiwan University Hospital |
2005-07 | |
| NCT00251017 | COMPLETED | Adverse Effects |
National Taiwan University Hospital |
2005-07 | |
| NCT00107978 | COMPLETED | Staphylococcal Skin Infection |
Cumberland Pharmaceuticals |
2005-02 | PHASE3 |
| NCT00107978 | COMPLETED | Staphylococcal Skin Infection |
Cumberland Pharmaceuticals |
2005-02 | PHASE3 |
| NCT00296049 | WITHDRAWN | Infection; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific |
Wake Forest University Health Sciences |
2005-07 | |
| NCT00296049 | WITHDRAWN | Infection; Neutropenia; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific |
Wake Forest University Health Sciences |
2005-07 | |
| NCT00228982 | COMPLETED | Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections |
Basilea Pharmaceutica |
2004-10 | PHASE3 |
| NCT00228982 | COMPLETED | Skin Diseases, Infectious; Skin Diseases, Bacterial; Staphylococcal Skin Infections |
Basilea Pharmaceutica |
2004-10 | PHASE3 |
| NCT00079976 | COMPLETED | Gram-Positive Bacterial Infections; Staphylococcus Infections; Vancomycin Resistance; Methicillin Resistance |
Wyeth is now a wholly owned subsidiary of Pfizer |
2003-10 | PHASE3 |
| NCT00079976 | COMPLETED | Gram-Positive Bacterial Infections; Staphylococcus Infections; Vancomycin Resistance; Methicillin Resistance |
Wyeth is now a wholly owned subsidiary of Pfizer |
2003-10 | PHASE3 |
| NCT00077675 | COMPLETED | Infections, Gram-positive Bacterial |
Cumberland Pharmaceuticals |
2004-02 | PHASE2 |
| NCT00077675 | COMPLETED | Infections, Gram-positive Bacterial |
Cumberland Pharmaceuticals |
2004-02 | PHASE2 |
| NCT00050401 | COMPLETED | Pneumonia |
Pfizer |
2002-07 | PHASE3 |
| NCT00050401 | COMPLETED | Pneumonia |
Pfizer |
2002-07 | PHASE3 |
| NCT00061633 | COMPLETED | Infections, Gram-Positive Bacterial; Abscess; Burns; Cellulitis; Ulcer; Wound Infections |
Cumberland Pharmaceuticals |
2003-06 | PHASE2 |
| NCT00061633 | COMPLETED | Infections, Gram-Positive Bacterial; Abscess; Burns; Cellulitis; Ulcer; Wound Infections |
Cumberland Pharmaceuticals |
2003-06 | PHASE2 |
| NCT00228410 | COMPLETED | Skin Diseases, Infectious |
Wyeth is now a wholly owned subsidiary of Pfizer |
2002-11 | PHASE3 |
| NCT00228410 | COMPLETED | Skin Diseases, Infectious |
Wyeth is now a wholly owned subsidiary of Pfizer |
2002-11 | PHASE3 |
| NCT01878643 | COMPLETED | Respiratory Infection; Bacterial Resistance; Respiratory Failure |
Stony Brook University |
2001-12 | EARLY_PHASE1 |
| NCT01878643 | COMPLETED | Respiratory Infection; Bacterial Resistance; Respiratory Failure |
Stony Brook University |
2001-12 | EARLY_PHASE1 |
| NCT00003805 | COMPLETED | Bone Marrow Suppression; Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific |
European Organisation for Research and Treatment of Cancer - EORTC |
1997-11 | PHASE3 |
| NCT00003805 | COMPLETED | Bone Marrow Suppression; Fever, Sweats, and Hot Flashes; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Unspecified Adult Solid Tumor, Protocol Specific; Unspecified Childhood Solid Tumor, Protocol Specific |
European Organisation for Research and Treatment of Cancer - EORTC |
1997-11 | PHASE3 |
| NCT00138112 | COMPLETED | Streptococcal Sepsis; Hematologic Malignancies |
Memorial Sloan Kettering Cancer Center |
2003-11 | PHASE3 |
| NCT00138112 | COMPLETED | Streptococcal Sepsis; Hematologic Malignancies |
Memorial Sloan Kettering Cancer Center |
2003-11 | PHASE3 |
| NCT00572559 | COMPLETED | Pneumonia, Ventilator-Associated |
Pfizer |
2002-11 | PHASE4 |
| NCT00572559 | COMPLETED | Pneumonia, Ventilator-Associated |
Pfizer |
2002-11 | PHASE4 |
| NCT00217841 | COMPLETED | Staphylococcal Infections |
NeuTec Pharma |
2004-01 | PHASE3 |
| NCT00217841 | COMPLETED | Staphylococcal Infections |
NeuTec Pharma |
2004-01 | PHASE3 |
| NCT00451373 | UNKNOWN | Acute Renal Failure; Sepsis; Postoperative |
National Taiwan University Hospital |
2006-07 | |
| NCT00451373 | UNKNOWN | Acute Renal Failure; Sepsis; Postoperative |
National Taiwan University Hospital |
2006-07 | |
| NCT00196794 | COMPLETED | Clostridium Enterocolitis; Diarrhea |
Genzyme, a Sanofi Company |
2005-04 | PHASE3 |
| NCT00196794 | COMPLETED | Clostridium Enterocolitis; Diarrhea |
Genzyme, a Sanofi Company |
2005-04 | PHASE3 |
| NCT00150852 | UNKNOWN | Wound Infection |
University Hospital, Geneva |
2004-09 | PHASE2 |
| NCT00150852 | UNKNOWN | Wound Infection |
University Hospital, Geneva |
2004-09 | PHASE2 |
| NCT00108433 | TERMINATED | Bacteremia; Gram-Positive Bacterial Infections |
Pfizer |
2005-09 | PHASE3 |
| NCT00396578 | COMPLETED | Ventilator Associated Pneumonia; Respiratory Infection; Tracheobronchitis |
Stony Brook University |
2003-08 | PHASE2 |
| NCT00108433 | TERMINATED | Bacteremia; Gram-Positive Bacterial Infections |
Pfizer |
2005-09 | PHASE3 |
| NCT00396578 | COMPLETED | Ventilator Associated Pneumonia; Respiratory Infection; Tracheobronchitis |
Stony Brook University |
2003-08 | PHASE2 |
| NCT00035854 | COMPLETED | Bacterial Infections |
Pfizer |
2002-02 | PHASE3 |
| NCT00035854 | COMPLETED | Bacterial Infections |
Pfizer |
2002-02 | PHASE3 |
| NCT00034294 | COMPLETED | Clostridium Difficile-Associated Diarrhea; Clostridium Enterocolitis; Clostridium Difficile Diarrhea; Antibiotic-associated Colitis; Antibiotic-associated Diarrhea |
Genzyme, a Sanofi Company |
2002-02 | PHASE2 |
| NCT00034294 | COMPLETED | Clostridium Difficile-Associated Diarrhea; Clostridium Enterocolitis; Clostridium Difficile Diarrhea; Antibiotic-associated Colitis; Antibiotic-associated Diarrhea |
Genzyme, a Sanofi Company |
2002-02 | PHASE2 |
| NCT00037050 | COMPLETED | Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia |
Pfizer |
2002-04 | PHASE3 |
| NCT00037050 | COMPLETED | Bacterial Infections; Gram-Positive Bacterial Infections; Bacteremia |
Pfizer |
2002-04 | PHASE3 |
| NCT00281281 | COMPLETED | Extracorporeal Membrane Oxygenation |
National Taiwan University Hospital |
2005-12 | PHASE4 |
| NCT00281281 | COMPLETED | Extracorporeal Membrane Oxygenation |
National Taiwan University Hospital |
2005-12 | PHASE4 |
| NCT00057369 | UNKNOWN | Bacteremia |
Vicuron Pharmaceuticals |
2001-02 | PHASE2 |
| NCT00057369 | UNKNOWN | Bacteremia |
Vicuron Pharmaceuticals |
2001-02 | PHASE2 |
| NCT00035425 | COMPLETED | Febrile Neutropenia |
Pfizer |
2001-11 | PHASE3 |
| NCT00035425 | COMPLETED | Febrile Neutropenia |
Pfizer |
2001-11 | PHASE3 |
(data from https://clinicaltrials.gov, updated on 2025-11-03)
Check the
Vancomycin
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
Note: Technical data last updated: Sep 1, 2026.